



THE UNIVERSITY *of* EDINBURGH

Edinburgh Research Explorer

Genetic landscape of chronic obstructive pulmonary disease identifies heterogeneous cell-type and phenotype associations

Citation for published version:

SpiroMeta Consortium, Int COPD Genetics Consortium & Understanding Soc Sci Grp 2019, 'Genetic landscape of chronic obstructive pulmonary disease identifies heterogeneous cell-type and phenotype associations', *Nature Genetics*, vol. 51, no. 3, pp. 494-+. <https://doi.org/10.1038/s41588-018-0342-2>

Digital Object Identifier (DOI):

[10.1038/s41588-018-0342-2](https://doi.org/10.1038/s41588-018-0342-2)

Link:

[Link to publication record in Edinburgh Research Explorer](#)

Document Version:

Peer reviewed version

Published In:

Nature Genetics

General rights

Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy

The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.



Genetic landscape of chronic obstructive pulmonary disease identifies heterogeneous cell type and phenotype associations

Phuwanat Sakornsakolpat^{1,2,51}, Dmitry Prokopenko^{1,3,51}, Maxime Lamontagne⁴, Nicola F. Reeve⁵, Anna L. Guyatt⁵, Victoria E. Jackson⁵, Nick Shrine⁵, Dandi Qiao¹, Traci M. Bartz^{6,7,8}, Deog Kyeom Kim⁹, Mi Kyeong Lee¹⁰, Jeanne C. Latourelle¹¹, Xingnan Li¹², Jarrett D. Morrow¹, Ma'en Obeidat¹³, Annah B. Wyss¹⁰, Per Bakke¹⁴, R Graham Barr¹⁵, Terri H. Beaty¹⁶, Steven A. Belinsky¹⁷, Guy G. Brusselle^{18,19,20}, James D. Crapo²¹, Kim de Jong^{22,23}, Dawn L. DeMeo^{1,24}, Tasha E. Fingerlin^{25,26}, Sina A. Gharib²⁷, Amund Gulsvik¹⁴, Ian P. Hall^{28,29}, John E. Hokanson³⁰, Woo Jin Kim³¹, David A. Lomas³², Stephanie J. London¹⁰, Deborah A. Meyers¹², George T. O'Connor^{33,34}, Stephen I. Rennard^{35,36}, David A. Schwartz^{37,38}, Pawel Sliwinski³⁹, David Sparrow⁴⁰, David P. Strachan⁴¹, Ruth Tal-Singer⁴², Yohannes Tesfaigzi¹⁷, Jørgen Vestbo⁴³, Judith M. Vonk^{22,23}, Jae-Joon Yim⁴⁴, Xiaobo Zhou¹, Yohan Bossé^{4,45}, Ani Manichaikul^{46,47}, Lies Lahousse^{48,18}, Edwin K. Silverman^{1,24}, H. Marika Boezen^{22,23}, Louise V. Wain^{5,49}, Martin D. Tobin^{5,49}, Brian D. Hobbs^{1,24,52}, Michael H. Cho^{1,24,52}, SpiroMeta Consortium⁵⁰, International COPD Genetics Consortium⁵⁰

1 Channing Division of Network Medicine, Brigham and Women's Hospital, Boston, MA, USA

2 Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand

3 Genetics and Aging Research Unit, Department of Neurology, Massachusetts General Hospital, Boston, MA, USA

4 Institut universitaire de cardiologie et de pneumologie de Québec, Québec, Canada

5 Genetic Epidemiology Group, Department of Health Sciences, University of Leicester, Leicester, UK

6 Cardiovascular Health Research Unit, University of Washington, Seattle, WA, USA

7 Department of Medicine, University of Washington, Seattle, WA, USA

8 Department of Biostatistics, University of Washington, Seattle, WA, USA

9 Seoul National University College of Medicine, SMG-SNU Boramae Medical Center, Seoul, South Korea

10 Epidemiology Branch, National Institute of Environmental Health Sciences, National Institutes of Health, Department of Health and Human Services, Research Triangle Park, NC, USA

11 Department of Neurology, Boston University School of Medicine, Boston, MA, USA

12 Department of Medicine, University of Arizona, Tucson, AZ

13 The University of British Columbia Center for Heart Lung Innovation, St Paul's Hospital, Vancouver, BC, Canada

14 Department of Clinical Science, University of Bergen, Bergen, Norway

15 Department of Medicine, College of Physicians and Surgeons and Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY, USA

16 Department of Epidemiology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, USA

17 Lovelace Respiratory Research Institute, Albuquerque, NM, USA

18 Department of Epidemiology, Erasmus Medical Center, Rotterdam, the Netherlands

19 Department of Respiratory Medicine, Ghent University Hospital, Ghent, Belgium

20 Department of Respiratory Medicine, Erasmus Medical Center, Rotterdam, the Netherlands
21 Department of Medicine, Division of Pulmonary and Critical Care Medicine, National Jewish Health, Denver, CO, USA
22 University of Groningen, University Medical Center Groningen, Department of Epidemiology, Groningen, the Netherlands
23 University of Groningen, University Medical Center Groningen, Groningen Research Institute for Asthma and COPD (GRIAC), Groningen, the Netherlands
24 Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Boston, MA, USA
25 Center for Genes, Environment and Health, National Jewish Health, Denver, CO, USA
26 Department of Biostatistics and Informatics, University of Colorado Denver, Aurora, CO, USA
27 Computational Medicine Core, Center for Lung Biology, UW Medicine Sleep Center, Department of Medicine, University of Washington, Seattle, WA, USA
28 Division of Respiratory Medicine, Queen's Medical Centre, University of Nottingham, Nottingham, UK
29 National Institute for Health Research Nottingham Biomedical Research Centre, Nottingham, UK
30 Department of Epidemiology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA
31 Department of Internal Medicine and Environmental Health Center, School of Medicine, Kangwon National University, Chuncheon, South Korea
32 UCL Respiratory, University College London, London, UK
33 The National Heart, Lung, and Blood Institute's Framingham Heart Study, Framingham, MA, USA
34 Pulmonary Center, Department of Medicine, Boston University School of Medicine, Boston, MA, USA
35 Pulmonary, Critical Care, Sleep and Allergy Division, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, USA
36 Clinical Discovery Unit, AstraZeneca, Cambridge, UK
37 Department of Medicine, School of Medicine, University of Colorado Denver, Aurora, CO, USA
38 Department of Immunology, School of Medicine, University of Colorado Denver, Aurora, CO, USA
39 2nd Department of Respiratory Medicine, Institute of Tuberculosis and Lung Diseases, Warsaw, Poland
40 VA Boston Healthcare System and Department of Medicine, Boston University School of Medicine, Boston, MA, USA
41 Population Health Research Institute, St. George's University of London, London, UK
42 GSK R&D, Collegeville, PA, USA
43 School of Biological Sciences, University of Manchester, Manchester, UK
44 Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea
45 Department of Molecular Medicine, Laval University, Québec, Canada
46 Center for Public Health Genomics, University of Virginia, Charlottesville, VA, USA
47 Department of Public Health Sciences, University of Virginia, Charlottesville, VA, USA

48 Department of Bioanalysis, Ghent University, Ghent, Belgium

49 National Institute for Health Research, Leicester Respiratory Biomedical Research Centre, Glenfield Hospital, Leicester, UK

50 A full list of authors appears at the end of the article

51 These authors contributed equally

52 These authors jointly supervised the work

Correspondence should be addressed to M.H.C. (remhc@channing.harvard.edu).

Abstract

Chronic obstructive pulmonary disease (COPD) is the leading cause of respiratory mortality worldwide. Genetic risk loci provide novel insights into disease pathogenesis. We performed a genome-wide association study in 35,735 cases and 222,076 controls from the UK Biobank and additional studies from the International COPD Genetics Consortium. We identified 82 loci with P -value $< 5 \times 10^{-8}$; 47 were previously described in association with either COPD or population-based lung function. Of the remaining 35 novel loci, 13 were associated with lung function in 79,055 individuals from the SpiroMeta consortium. Using gene expression and regulation data, we identified enrichment for loci in lung tissue, smooth muscle and several lung cell types. We found 14 COPD loci shared with either asthma or pulmonary fibrosis. COPD genetic risk loci clustered into groups of quantitative imaging features and comorbidity associations. Our analyses provide further support to the genetic susceptibility and heterogeneity of COPD.

Introduction

Chronic obstructive pulmonary disease (COPD) is a disease of enormous and growing global burden¹, ranked third as a global cause of death by the World Health Organization in 2016². Environmental risk factors, predominately cigarette smoking, account for a large fraction of disease risk, but there is considerable variability in COPD susceptibility among individuals with similar smoking exposure. Studies in families and in populations demonstrate that genetic factors account for a substantial fraction of disease susceptibility. Similar to other adult-onset complex diseases, common variants likely account for the majority of population genetic susceptibility^{3,4}. Our previous efforts identified 22 genome-wide significant loci⁵. Expanding the number of loci can lead to novel insights into disease pathogenesis, not only through discovery of novel biology at individual loci^{6,7}, but also across loci via identification functional links and specific cell types and phenotypes⁵.

We performed a genome-wide association study combining previously described studies from the International COPD Genetics Consortium (ICGC)⁵ with additional subjects from the UK Biobank⁸, a population-based study of several hundred thousand subjects with lung function and cigarette smoking assessment. We determined, through bioinformatic and computational analysis, the likely set of variants, genes, cell types, and biologic pathways implicated by these associations. Finally, we assessed our genetic findings for relevance to COPD-specific, respiratory, and other phenotypes.

Results

Genome-wide association study of COPD

We included a total of 257,811 individuals from 25 studies in the analysis, including studies from International COPD Genetics Consortium and UK Biobank (**Figure 1**). We defined COPD based on pre-bronchodilator spirometry according to modified Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria for moderate to very severe airflow limitation⁹, as done previously⁵. This definition resulted in 35,735 cases and 222,076 controls (**Supplementary Table 1**). We tested association of COPD and 6,224,355 variants in a meta-analysis of 25 studies using a fixed-effects model. We found no evidence of confounding by population substructure using linkage disequilibrium score regression¹⁰ (LDSC) intercept (1.0377, s.e. 0.0094). We identified 82 loci (defined using 2-Mb windows) at genome-wide significance ($P < 5 \times 10^{-8}$) (**Figure 1 and 2; Supplementary Figures 1 and 2**). Forty-seven of 82 loci were previously described as genome-wide significant in COPD^{5,11} or lung function^{12–20} (**Supplementary Table 2**), leaving 35 novel loci (**Table 1**) at the time of analysis. We then sought to replicate these loci. Given the strong genetic correlation between population-based lung function and COPD, we tested the lead variant at each locus for association with forced expiratory volume in 1 s (FEV₁) or FEV₁/forced vital capacity (FVC) in 79,055 individuals from SpiroMeta²¹ (**Supplementary Table 3**). We identified 13 loci – *C1orf87*, *DENND2D*, *DDX1*, *SLMAP*, *BTC*, *FGF18*, *CITED2*, *ITGB8*, *STN1*, *ARNTL*, *SERP2*, *DTWD1*, and *ADAMTSL3* – that replicated using a Bonferroni correction for a one-sided $P < 0.05/35$; **Table 1**). Although not meeting the strict Bonferroni threshold, additional 14 novel loci were nominally significant in SpiroMeta (consistent direction of effect and one-sided $P < 0.05$): *ASAP2*, *EML4*, *VGLL4*, *ADCY5*, *HSPA4*, *CCDC69*, *RREB1*, *ID4*, *IER3*, *RFX6*, *MFHAS1*, *COL15A1*, *TEPP*, and *THRA* (**Table 1**), and all 82 loci showed consistent direction of effect with either FEV₁ or FEV₁/FVC ratio in SpiroMeta (**Table 1** and Error! Reference source not found.). We note that 9 of our 35 novel loci were recently described in a contemporaneous analysis of lung function in UK Biobank²¹. None of the novel loci appeared to be explained by cigarette smoking, and variant effect sizes in ever- and never-smokers and including and excluding self-reported asthmatics were similar (**Supplementary Note**). In addition, we found no significant differences in variant effects by sex (**Supplementary Note**). Including all 82 genome-wide significant variants, we explain up to 7.0% of the phenotypic variance in liability scale, using a 10% prevalence of COPD, acknowledging that these effects are likely overestimated in the discovery sample. This represents up to a 48% increase in COPD phenotypic variance explained by genetic loci compared to the 4.7% explained by 22 loci reported in a recent GWAS of COPD⁵.

Identification of secondary association signals

We used approximate conditional and joint analysis²² to find secondary signals at each of the 82 genome-wide significant loci. We found 82 secondary signals at 50 loci, resulting in a total of 164 independent associations in 82 loci (**Supplementary Table 4**). Of 50 loci containing secondary associations, 33 were at loci previously described for COPD or lung function, and six at Bonferroni-replicated novel loci. Of 82 secondary associations, 20 reached genome-wide significance ($P < 5 \times 10^{-8}$) (**Supplementary Table 4**). Of 61 novel (not previously described in COPD or lung function) independent associations, 21 reached a region-wise Bonferroni-corrected threshold (one-sided $P < 0.05/\text{novel independent association(s) in each locus}$) in unconditioned associations from SpiroMeta (**Methods** and **Supplementary Table 4**).

Tissue and specific cell types

In determining the tissue in which COPD genetic variants function to increase COPD risk, lung is the obvious tissue to consider. However, COPD is a systemic disease^{23,24} and within the lung the cell-types collectively contributing to disease pathogenesis are largely unknown.

Furthermore, available databases include cell types relevant to lung (e.g. smooth muscle) but from other organs (e.g. the gastrointestinal tract). To identify putative causal tissues and cell types, we assessed the heritability enrichment in integrated genome annotations at the single tissue level²⁵ and tissue-specific epigenomic marks²⁶. Lung tissue showed the most significant enrichment (enrichment = 9.25, $P = 1.36 \times 10^{-9}$), as previously described, though significant enrichment was also seen in heart (enrichment = 6.85, $P = 3.83 \times 10^{-8}$) and the gastrointestinal (GI) tract (enrichment = 5.53, $P = 6.45 \times 10^{-11}$). In an analysis of enriched epigenomic marks, the most significant enrichment was in fetal lung and GI smooth muscle DNase hypersensitivity sites (DHS) ($P = 6.75 \times 10^{-8}$) and H3K4me1 ($P = 7.31 \times 10^{-7}$) (**Supplementary Table 5**). To identify the source of association within lung tissue, we tested for heritability enrichment using single-cell chromatin accessibility²⁷ (ATAC-Seq) and gene expression (RNA-Seq) from human^{28,29} and murine³⁰ lung (**Supplementary Table 5**). Using LD score regression in murine ATAC-Seq data, we found enrichment of chromatin accessibility in several cell types, including endothelial cells (most significant), type 1, and type 2 alveolar cells (the latter among the highest fold-enrichment [**Supplementary Table 5a**]). Results using LD score regression³¹ or SNPsea³² on single-cell RNA-Seq varied, with nominal P -values for genes expressed in type 2 alveolar cells, basal-like cells, club cells, fibroblasts and smooth muscle cells (**Supplementary Tables 5b,c**).

Fine-mapping of associated loci

To identify the most likely causal variants at each locus, we performed fine mapping using Bayesian credible sets³³. Including 160 potential primary and secondary association signals (excluding four variants in the major histocompatibility complex [MHC] region), 61 independent signals had a 99% credible set with fewer than 50 variants; 34 signals had credible sets with fewer than 20 variants (**Supplementary Figure 3**). Eighteen loci had a single variant with a posterior probability of driving association (PPA) greater than 60% including the *NPNT* (4q24) locus, where the association could be fine-mapped to a single intronic variant, rs34712979 (NC_000004.11:g.106819053G>A, see **Supplementary Note** and **Supplementary Table 6**). Most sets included variants that overlapped genic enhancers of lung-related cell types (e.g., fetal lung fibroblasts, fetal lung, and adult lung fibroblasts) and were predicted to alter transcription binding motifs (**Supplementary Table 6**). Of 61 credible sets with fewer than 50 variants, eight sets contained at least one deleterious variant. These deleterious variants included 1) missense variants affecting *TNS1*, *RIN3*, *ADGRG6*, *ADAM19*, *ATP13A2*, *BTC*, and *CRLF3*; and 2) a splice donor variant affecting a lincRNA - AP003059.2.

Candidate target genes

In most cases, the closest gene to a lead SNP will not be the gene most likely to be the causal or effector gene of disease-associated variants^{34–36}. Thus, to identify the potential effector ('target') genes underlying these genetic associations, we integrated additional molecular information including gene expression, gene regulation (open chromatin and methylation data), chromatin interaction, co-regulation of gene expression with gene sets, and coding variant data (**Methods** and **Figure 3**).

At 82 loci, 472 genes within +/- 1 Mb of top associated variants were implicated by analysis of least one dataset; 106 genes were implicated by lung gene expression^{37,38}, and an additional 50 genes by >= 2 other datasets (methylation³⁹, chromatin interaction⁴⁰, open chromatin regions⁴¹, similarity in gene sets⁴² or deleterious coding variants⁴³ [**Figure 3**]), for a total of 156 genes meeting more stringent criteria. Excluding loci in the MHC region, the median number of potentially implicated genes per locus was four, with a maximum of 17 genes (7q22.1 and 17q21.1). The median distance of implicated genes to top associated variants was 346 Kb. Among 82 loci, 60 (73%) included the nearest gene. We identified 20 genes with supportive evidence from exome sequencing data. Two genes (*ADAM19* and *ADAMTSL3*) were implicated by five datasets (**Figure 3**) and another two (*EML4* and *RIN3*) were implicated by four datasets. A summary of all genes implicated using these approaches is included in **Supplementary Table 7**.

Associated pathways

To gain further functional insight of associated genetic loci, we performed gene-set enrichment analysis using DEPICT⁴². Among 165 enriched gene sets at false discovery rate (FDR) < 5%, 44% of them were related to the developmental process term, with nominal *P* for lung development of 1.02×10^{-6} ; significant sub-terms included lung alveolus development (*P* = 0.0003) and lung morphogenesis (*P* = 0.0005). We also found enrichment of extracellular matrix-related pathways including laminin binding, integrin binding, mesenchyme development, cell-matrix adhesion, and actin filament bundles. Additional pathways of note included histone deacetylase binding, the Wnt receptor signaling pathway, SMAD binding, the MAPK cascade, and the transmembrane receptor protein serine/threonine kinase signaling pathway. Full enrichment analysis results including the top genes for each DEPICT gene set are shown in **Supplementary Table 8**.

Identification of drug targets

GWAS is also useful for identifying drug targets either at the individual gene^{18,44,45} or genome-wide level^{46,47}. Of 482 candidate target genes, 60 genes could be targeted by at least one approved or in-development drug⁴⁸, totaling 428 drugs with 144 different modes of action (**Supplementary Table 9**). Druggable targets at novel loci for COPD and lung function included *ABHD6*, *CDKL2*, *GSTO2*, *KCNC4*, *PDHB*, *SLK*, and *TRPM7*. We also identified drugs for repurposing in COPD using transcriptome-wide associations and drug-induced gene expression signatures⁴⁹ (**Supplementary Note**).

Phenotypic effects of COPD-associated variants

To characterize the phenotypic effects of 82 genome-wide significant loci, we performed a phenome-wide association analysis within the deeply phenotyped COPD Gene study (**Methods**). We assessed for common patterns of phenotype associations for the 82 loci by using hierarchical clustering across scaled Z scores of phenotype-variant associations. We identified two clusters of variants differentially associated with two sets of phenotypes (**Supplementary Figure 4**). As these two variant-phenotype clusters appeared to be driven by computed tomography (CT) imaging features, we repeated variant clustering limited to quantitative computed tomography imaging features. We again found two clusters of variants, differentiated by association with quantitative emphysema, emphysema distribution, gas trapping, and airway phenotypes (**Figure 4a**). Additionally, we evaluated the association of the 82 genome-wide significant variants in a prior GWAS of emphysema and airway quantitative computed tomography features⁵⁰ (**Supplementary Table 10**).

We also examined all genome-wide significant loci in the NHGRI-EBI GWAS Catalog⁵¹ (**Supplementary Figure 5, Supplementary Table 11**) and looked for trait-associated variants in linkage disequilibrium ($r^2 > 0.2$) with our lead COPD-associated variants. Many variants were associated with anthropometric measures including height and body mass index (BMI), measurements on blood cells (red and white cells), and cancers. COPD is well known to have many common comorbidities, such as coronary artery disease (CAD), type 2 diabetes mellitus (T2D), osteoporosis, and lung cancer. Of these diseases and 13 additional traits, we confirmed previously reported overall genetic correlation (using linkage disequilibrium score regression⁵²) of COPD with lung function, asthma, and height, and found evidence of modest correlation between COPD and lung cancer (**Supplementary Note**). However, at individual loci, and using more stringent linkage disequilibrium ($r^2 > 0.6$), we found evidence of shared risk factors for these comorbid diseases and COPD including a genome-wide significant variant near *PABPC4* associated with T2D, four variants with CAD (near *CFDP1*, *DMWD*, *STN1*, and *TNS1*), and a variant near *SPPL2C* with bone density (**Figure 4b**).

Overlapping loci with asthma and pulmonary fibrosis

Based on our previous identification of genetic overlap of COPD with asthma, and COPD with pulmonary fibrosis, we examined loci for specific overlap with these two diseases. In asthma, we noted an $r^2 > 0.2$ with one of our variants and previously reported variants at *ID2*, *ZBTB38*, *C5orf56*, *MICA*, *AGER*, *HLA-DQB1*, *ITGB8*, *CLEC16A*, and *THRA*. In pulmonary fibrosis, in addition to our previously described overlap at *FAM13A*, *DSP*, and 17q21, we noted overlapping associations at *ZKSCAN1* and *STN1* (**Supplementary Table 12**). To more closely examine overlap, we applied a Bayesian method (gwas-pw⁵³) of COPD associations from our current GWAS with previous GWASs of asthma (limited to those of European ancestry) and pulmonary fibrosis^{54,55}. To mitigate the results of including asthma among our COPD cases, we performed analysis for overlap with asthma removing self-reported asthmatics from UK Biobank for this analysis (**Methods**). We identified 14 shared genome segments (posterior probability $> 70\%$), 9 with asthma and 5 with pulmonary fibrosis (**Figure 4c, Supplementary Table 13**). In addition to the three segments shared with pulmonary fibrosis identified in the previous study⁵ (*FAM13A*, *DSP*, and the 17q21 locus – here nearest *CRHRI*), we identified two new segments including loci near *ZKSCAN1* and *STN1* (formerly known as *OBFC1*). Shared variants between COPD and pulmonary fibrosis all had an opposite effect (i.e., increasing risk for COPD but protective for pulmonary fibrosis). In asthma, we identified five shared segments in the 6p21-22 regions, as well as *ADAM19*, *ARMC2*, *ELAVL2*, and *STAT6*. With the exception of *STAT6*, overlapping variants showed the same direction of effect.

Discussion

Genetic factors play an important role in COPD susceptibility. We examined genetic risk of COPD in a genome-wide association study of 35,735 cases and 222,076 controls. We identified 82 genome-wide significant loci for COPD, of which 47 were previously identified in genome-wide association studies of COPD or population-based lung function. Of 35 loci not previously described at the time of analysis, 13 replicated in an independent study of population-based lung function. We used several data sources to attempt to assign causal genes at each locus, identifying 156 genes at 82 loci that were supported by either gene expression or a combination of at least 2 other data sources. Our results identify specific genes, cell types, and biologic

pathways for targeted study and also suggest a genetic basis for the clinical heterogeneity seen in COPD.

Our study supports the role of early life events in the risk of COPD. Gene set enrichment analysis identified developmental pathways both specific to the lung (e.g., lung morphogenesis and lung alveolar development) and related to the lung (e.g., the canonical Wnt receptor^{56,57}, the MAPK/ERK, and the nerve growth factor receptor signaling pathways). We also confirmed enrichment of heritability in epigenomic marks of fetal lung. Our findings are consistent with epidemiologic studies demonstrating that a substantial portion of the risk of COPD may develop in early life: genetic variants may set initial lung function⁵⁸ and patterns of growth^{58–60}. While further work will be needed to confirm the causal variants and genes affected by our variants, testing the role of these genes in lung development-relevant murine or ex-vivo models – for example, determining whether the perturbation of these genes changes proliferation and differentiation of lung epithelial progenitors in induced pluripotent cell-derived lung alveolar type 2 cells⁴⁴ – could provide experimental evidence of the role of these genes in early life susceptibility. Ultimately, the goal of this work would be to identify targets for or subsets of high risk individuals early in the disease course, or molecular candidates that may affect lung repair and regeneration⁶¹.

Apart from genes related to lung development, our analyses highlighted several genes and pathways already of interest in COPD therapy (e.g. *CHRM3* / acetylcholine receptor inhibitors, the *MAPK* pathway) – supporting the role of genetic analyses in finding therapeutic targets^{18,62} – and newer genes that could inform future functional studies. We identified interleukin 17 receptor D (*IL17RD*), as a potential effector gene at the 3p14 locus. Numerous studies have examined the role of IL-17A in COPD⁶³, and *IL17RD* can differentially regulate pathways employed by IL-17A⁶⁴. Chitinase acidic (*CHIA*) at 1p13.3, which encodes a protein that degrades chitin⁶⁵, exhibits lung-specific expression^{66,67}. *CHIA* variants have been associated with FEV₁⁶⁸, asthma^{69–72}, and acid mammalian chitinase activity^{71,73}. We identified several potential effector genes related to extracellular matrix, cell adhesion, cell-cell interactions, and elastin-associated microfibrils^{74–76}, some of which have been previously identified in studies of lung function¹⁵. These include integrin family members that mediate cell-matrix communication (e.g., *ITGA1*, *ITGA2*, *ITGA8*^{77–79}), an integrin ligand encoding gene (*NPNT*⁸⁰), and genes encoding matrix proteins (e.g., *MFAP2* and *ADAMTSL3*). *ADAMTSL3* plays a role in cell-matrix interactions related to the assembly of fibrillin and microfibril biogenesis^{81–83} and of our candidate effector genes was supported by the greatest number of bioinformatic analyses. Recombinant forms of other *ADAMTS*-like proteins demonstrate experimental evidence of promoting and enhancing fibrillin and microfibril deposition and assembly^{84,85}. *ADAMTSL3* may play a role in preventing emphysematous destruction of lung tissue by *ADAMTS* in COPD. In addition to identifying the effector gene, knowing the effector cell type is critical for functional studies. We identified an overall enrichment of epigenomic marks in lung tissue and smooth muscle (also identified in studies of lung function¹⁶). This latter association was found in gastrointestinal tissue cell types; respiratory smooth muscle is absent in the analyzed datasets. We also performed analyses of single-cell data in an attempt to identify the specific lung cell types in which our top variants are potentially functioning. We found evidence for enrichment of several cell types, including but not limited to endothelial cells, alveolar type 2 cells, and basal-like cells. Each of these cell types has been postulated to have a role in the development of COPD^{86–88}, and our data are consistent with the likely heterogeneity of lung cell types contributing to COPD susceptibility. The lung comprises at least 40 different resident cell

types⁸⁹, most of which are not distinctly represented in these datasets. Thus, while our findings support the investigation of specific cell types for further functional studies, they also highlight the need for profiling of lung-relevant cell types and loci-specific analyses. Characterization of functional variant effects could lead to better disease subtyping and more targeted therapy for COPD. Cluster analysis on hundreds of COPD-associated features in the more extensively phenotyped COPD Gene cohort showed heterogeneous effects of genetic variants on COPD-related phenotypes, including computed tomography (CT) measurements of airway abnormalities and emphysema – well-described sources of heterogeneity in COPD⁹⁰⁻⁹². Analyzing hundreds of diseases/traits in GWAS Catalog, we identified overlapping associations with various diseases/traits in multiple organ systems, comorbidities such as coronary artery disease, bone mineral density, and type 2 diabetes mellitus (T2D). The COPD-associated *PABPC4* locus was associated with T2D⁹³ and C-reactive protein (CRP) level⁹⁴. Although a causal gene in this locus and its contribution to COPD is unknown, its association with T2D may suggest a shared disease pathway and drug targets. Together, the identification of variable COPD risk loci associations with sub-phenotypes and other diseases^{95,96} may have potential for more nuanced approaches to therapy for COPD. Overall, our phenotype, gene, and pathway analyses illustrate the utility of both searching for enrichment of genetic signals overall, and performing a more detailed identification of the effects of individual variants or groups of variants. We performed additional specific analysis in two diseases that overlap with COPD, asthma and pulmonary fibrosis. While a genome-wide genetic correlation of COPD and asthma has been previously described⁵, our analysis is the first to identify specific shared genetic segments between asthma and COPD. While the effects at most of these shared segments were concordant in direction, one of the segments of particular interest was near *STAT6*, which had opposite directions of effect in the two diseases. *STAT6* plays a role in T helper (Th) type 2-dependent inflammation, and is activated by interleukin-4 and interleukin-13 (IL-4 and IL-13)⁹⁷. IL-13, in turn, has been found to be increased in asthmatic airways⁹⁸ but decreased in severe emphysema⁹⁹. In pulmonary fibrosis, variants at all overlapping loci have an opposite direction of effect compared to COPD⁵. These effects raise the possibility that specific therapies for one disease could increase the risk of the other disease, which may be worth evaluating in treatment trials. The reasons why genetic effects are divergent between COPD and fibrosis are unclear, but these identified opposite effects could point to molecular switches that influence why some smokers develop emphysema while others develop pulmonary fibrosis. While pulmonary fibrosis is an uncommon disease and specifically excluded in several of our COPD case-control cohorts, interstitial lung abnormalities are increasingly being recognized as a potential precursor to fibrosis, and an inverse relationship between these abnormalities and emphysema has been previously identified¹⁰⁰. Mechanistically, some have hypothesized that the divergent derangement of Wnt and Notch signaling pathways¹⁰¹ and mesenchymal cell fate¹⁰² may be responsible for the distinct development of these two diseases. We also describe an overlapping region at the *STN1* (previously known as *OBFC1*) locus. *STN1* plays a role in telomere maintenance¹⁰³; shortened telomeres have been observed in both COPD and idiopathic pulmonary fibrosis (IPF)^{104,105}, and rare genetic variants in the telomerase pathway have been implicated in both pulmonary fibrosis and emphysema – albeit with concordant effects on either disease¹⁰⁶. While our study a large genome-wide association study of COPD, individuals meeting our criteria for COPD in the UK Biobank may be different from other studies, especially for smoking history. We used the same definition of COPD as in our prior analysis⁵, which included non-

smokers. Our use of pre-bronchodilator spirometry to define COPD (allowing us to maximize sample size) as well as population-based lung function for replication could bias our findings against variants that are only associated with more severe forms of COPD. We did not exclude other causes of airway obstruction such as asthma, noting that asthma frequently overlaps with, and is misdiagnosed in COPD¹⁰⁷. We performed several additional analyses to determine whether our results were driven by, or markedly different, by smoking status, asthma, or use of pre- instead of post-bronchodilator spirometry to define COPD. The results of these additional analyses did not indicate a substantial impact of these factors on our overall findings, and together with prior analyses^{5,16}, suggest that bias due to these factors is likely small. However, our study was not designed to identify differences between subgroups, and we cannot rule out a role for studying more severe disease or disease subtypes. We note that the alpha-1 antitrypsin locus (*SERPINA1*) was identified as genome-wide significant in smaller studies of emphysema and in smokers with severe COPD¹⁰⁸. In the current study, the association of the PiZ allele (NC_000014.8:g.94844947C>T, rs28929470) had $P = 2.2 \times 10^{-5}$ using moderate-to-severe cases ($FEV_1 < 80\%$ predicted), and a smaller P -value (1.4×10^{-6}) in severe cases ($FEV_1 < 50\%$ predicted) despite a smaller sample size, a phenomenon we have previously described¹¹. Thus, despite the strong overlap of COPD with quantitative spirometry, new loci may be identified through studies of sufficiently large subsets of COPD patients and with more specific and homogeneous COPD phenotypes. Given suggestive evidence for replication using a related (but not identical) phenotype for additional novel loci beyond the 13 meeting a Bonferroni-corrected threshold for significance, we chose to include all loci significant in discovery in subsequent analyses, recognizing that we likely included some false positive associations. Our study focused on relatively common variants, predominantly in individuals of European ancestry; more detailed studies of rare variants, the human leukocyte antigen (HLA) regions, and other ethnicities are warranted, but broader multi-ethnic analyses are limited by the number of cases in currently available cohorts. Although COPD sex differences have been reported¹⁰⁹, we did not identify significant sex-specific differences in effect sizes of the 82 top variants. Future studies including more subjects and methodological advances may be needed to elucidate this effect. The global burden of COPD is increasing. Our work finds a substantial number of new loci for COPD and uses multiple lines of supportive evidence to identify potential genes and pathways for both existing and novel loci. Further investigation of the genetic overlap of COPD with other respiratory diseases and the phenotypic effects of top loci finds new shared loci for asthma and idiopathic pulmonary fibrosis and suggests heterogeneity across COPD-associated loci. Together, these insights provide multiple new avenues for investigation of the underlying biology and the potential therapeutics in this deadly disease.

Acknowledgements

This work was supported by the Prince Mahidol Award Youth Program Scholarship (P.S.); NHLBI R01HL084323, R01HL113264, R01HL089856, and P01HL105339 (E.K.S.); K08HL136928 (B.D.H.), the Parker B. Francis Research Opportunity Award (B.D.H.); R01HL113264, R01HL137927, P01HL105339 and P01HL132825 (M.H.C.). This research has been conducted using the UK Biobank Resource under application number 20915 (M.H.C.) and 648 (M.D.T.). Please refer to the **Supplementary Note** for full acknowledgements. The funding body has no role in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.

Author contributions

P.S. contributed to the study concept and design, data analysis, and manuscript writing. D.P., B.D.H., M.H.C. contributed to the study concept and design, data analysis, statistical support, and manuscript writing. A.B.W., K.d.J., S.J.L., D.P.S. contributed to the study concept and design and data analysis. P.B., R.G.B., J.D.C., A.G., D.A.M., G.T.O., S.I.R., D.A.S., R.T.-S., Y.T., E.K.S. contributed to the study concept and design and data collection. T.H.B., J.E.H. contributed to the study concept and design and to statistical support. I.P.H., H.M.B., L.V.W., M.D.T. contributed to the study concept and design. All authors, including those whose initials are not listed above, contributed to the critical review and editing of the manuscript and approved the final version of the manuscript.

Competing interests statement

M.H.C., E.K.S., L.V.W., M.D.T., D.A.L. and I.P.H. have received grant funding from GlaxoSmithKline (GSK). E.K.S. has received honoraria from Novartis for Continuing Medical Education Seminars and travel support from GSK. I.P.H. has received grant support from BI. R.T-S. is employee and shareholder of GSK. J.V. has received personal fees from GSK, Chiesi Pharmaceuticals, BI, Novartis, and AstraZeneca. D.L.D. has received grants from the National Institutes of Health for research of COPD and personal fees from Novartis. D.A.L. has received honoraria from GSK and chaired the Respiratory Therapy Area Board 2012-15. Outside the submitted work, L.L. reports expert consultation for Boehringer Ingelheim GmbH and Novartis and unrestricted grants from AstraZeneca and Chiesi.

References (for main text)

1. GBD 2015 Chronic Respiratory Disease Collaborators. Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. *Lancet. Respir. Med.* **5**, 691–706 (2017).
2. *Global Health Estimates 2016: Deaths by Cause, Age, Sex, by Country and by Region, 2000-2016.* (2018).
3. Fuchsberger, C. *et al.* The genetic architecture of type 2 diabetes. *Nature* **536**, 41–47 (2016).
4. Zhou, J. J. *et al.* Heritability of chronic obstructive pulmonary disease and related phenotypes in smokers. *Am. J. Respir. Crit. Care Med.* **188**, 941–7 (2013).
5. Hobbs, B. D. *et al.* Genetic loci associated with chronic obstructive pulmonary disease overlap with loci for lung function and pulmonary fibrosis. *Nat Genet* **49**, 426–432 (2017).
6. Jiang, Z. *et al.* A Chronic Obstructive Pulmonary Disease Susceptibility Gene, FAM13A, Regulates Protein Stability of beta-Catenin. *Am J Respir Crit Care Med* **194**, 185–197 (2016).
7. Lao, T. *et al.* Hhip haploinsufficiency sensitizes mice to age-related emphysema. *Proc. Natl. Acad. Sci. U. S. A.* **113**, E4681-7 (2016).
8. Sudlow, C. *et al.* UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. *PLoS Med.* **12**, e1001779 (2015).
9. Vogelmeier, C. F. *et al.* Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary. *Am. J. Respir. Crit. Care Med.* **195**, 557–582 (2017).

10. Bulik-Sullivan, B. K. *et al.* LD Score regression distinguishes confounding from polygenicity in genome-wide association studies. *Nat. Genet.* **47**, 291–5 (2015).
11. Cho, M. H. *et al.* Risk loci for chronic obstructive pulmonary disease: a genome-wide association study and meta-analysis. *Lancet Respir Med* **2**, 214–225 (2014).
12. Wilk, J. B. *et al.* A genome-wide association study of pulmonary function measures in the Framingham Heart Study. *PLoS Genet* **5**, e1000429 (2009).
13. Repapi, E. *et al.* Genome-wide association study identifies five loci associated with lung function. *Nat Genet* **42**, 36–44 (2010).
14. Hancock, D. B. *et al.* Meta-analyses of genome-wide association studies identify multiple loci associated with pulmonary function. *Nat Genet* **42**, 45–52 (2010).
15. Soler Artigas, M. *et al.* Genome-wide association and large-scale follow up identifies 16 new loci influencing lung function. *Nat Genet* **43**, 1082–1090 (2011).
16. Wain, L. V *et al.* Novel insights into the genetics of smoking behaviour, lung function, and chronic obstructive pulmonary disease (UK BiLEVE): a genetic association study in UK Biobank. *Lancet Respir Med* **3**, 769–781 (2015).
17. Soler Artigas, M. *et al.* Sixteen new lung function signals identified through 1000 Genomes Project reference panel imputation. *Nat Commun* **6**, 8658 (2015).
18. Wain, L. V *et al.* Genome-wide association analyses for lung function and chronic obstructive pulmonary disease identify new loci and potential druggable targets. *Nat. Genet.* **49**, 416–425 (2017).
19. Wyss, A. B. *et al.* Multiethnic meta-analysis identifies ancestry-specific and cross-ancestry loci for pulmonary function. *Nat. Commun.* **9**, 2976 (2018).
20. Jackson, V. E. *et al.* Meta-analysis of exome array data identifies six novel genetic loci for lung function. *Wellcome open Res.* **3**, 4 (2018).
21. Shrine, N. *et al.* New genetic signals for lung function highlight pathways and pleiotropy, and chronic obstructive pulmonary disease associations across multiple ancestries. *bioRxiv* (2018).
22. Yang, J. *et al.* Conditional and joint multiple-SNP analysis of GWAS summary statistics identifies additional variants influencing complex traits. *Nat. Genet.* **44**, 369–75, S1-3 (2012).
23. Agusti, A. & Soriano, J. B. COPD as a systemic disease. *COPD* **5**, 133–8 (2008).
24. Barnes, P. J. & Celli, B. R. Systemic manifestations and comorbidities of COPD. *Eur. Respir. J.* **33**, 1165–85 (2009).
25. Lu, Q. *et al.* Systematic tissue-specific functional annotation of the human genome highlights immune-related DNA elements for late-onset Alzheimer’s disease. *PLoS Genet.* **13**, e1006933 (2017).
26. Finucane, H. K. *et al.* Partitioning heritability by functional annotation using genome-wide association summary statistics. *Nat. Genet.* **47**, 1228–35 (2015).
27. Cusanovich, D. A. *et al.* A Single-Cell Atlas of In Vivo Mammalian Chromatin Accessibility. *Cell* **174**, 1309–1324.e18 (2018).
28. Xu, Y. *et al.* Single-cell RNA sequencing identifies diverse roles of epithelial cells in idiopathic pulmonary fibrosis. *JCI insight* **1**, e90558 (2016).
29. Jacob, A. *et al.* Differentiation of Human Pluripotent Stem Cells into Functional Lung Alveolar Epithelial Cells. *Cell Stem Cell* **21**, 472–488.e10 (2017).
30. Ardini-Poleske, M. E. *et al.* LungMAP: The Molecular Atlas of Lung Development Program. *Am. J. Physiol. Lung Cell. Mol. Physiol.* **313**, L733–L740 (2017).

31. Finucane, H. K. *et al.* Heritability enrichment of specifically expressed genes identifies disease-relevant tissues and cell types. *Nat. Genet.* **50**, 621–629 (2018).
32. Slowikowski, K., Hu, X. & Raychaudhuri, S. SNPsea: an algorithm to identify cell types, tissues and pathways affected by risk loci. *Bioinformatics* **30**, 2496–7 (2014).
33. Wakefield, J. A Bayesian measure of the probability of false discovery in genetic epidemiology studies. *Am. J. Hum. Genet.* **81**, 208–27 (2007).
34. Visscher, P. M. *et al.* 10 Years of GWAS Discovery: Biology, Function, and Translation. *Am. J. Hum. Genet.* **101**, 5–22 (2017).
35. Zhou, X. *et al.* Identification of a chronic obstructive pulmonary disease genetic determinant that regulates HHIP. *Hum. Mol. Genet.* **21**, 1325–35 (2012).
36. Claussnitzer, M., Hui, C.-C. & Kellis, M. FTO Obesity Variant and Adipocyte Browning in Humans. *N. Engl. J. Med.* **374**, 192–3 (2016).
37. Barbeira, A. N. *et al.* Exploring the phenotypic consequences of tissue specific gene expression variation inferred from GWAS summary statistics. *Nat. Commun.* **9**, 1825 (2018).
38. Lamontagne, M. *et al.* Leveraging lung tissue transcriptome to uncover candidate causal genes in COPD genetic associations. *Hum. Mol. Genet.* **27**, 1819–1829 (2018).
39. Morrow, J. D. *et al.* Human Lung DNA Methylation Quantitative Trait Loci Colocalize with COPD Genome-wide Association Loci. *Am. J. Respir. Crit. Care Med.* (2018). doi:10.1164/rccm.201707-1434OC
40. Schmitt, A. D. *et al.* A Compendium of Chromatin Contact Maps Reveals Spatially Active Regions in the Human Genome. *Cell Rep.* **17**, 2042–2059 (2016).
41. Shooshtari, P., Huang, H. & Cotsapas, C. Integrative Genetic and Epigenetic Analysis Uncovers Regulatory Mechanisms of Autoimmune Disease. *Am. J. Hum. Genet.* **101**, 75–86 (2017).
42. Pers, T. H. *et al.* Biological interpretation of genome-wide association studies using predicted gene functions. *Nat. Commun.* **6**, 5890 (2015).
43. Qiao, D. *et al.* Whole exome sequencing analysis in severe chronic obstructive pulmonary disease. *Hum. Mol. Genet.* (2018). doi:10.1093/hmg/ddy269
44. Sanseau, P. *et al.* Use of genome-wide association studies for drug repositioning. *Nat. Biotechnol.* **30**, 317–20 (2012).
45. Lencz, T. & Malhotra, A. K. Targeting the schizophrenia genome: a fast track strategy from GWAS to clinic. *Mol. Psychiatry* **20**, 820–6 (2015).
46. Lamb, J. *et al.* The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. *Science* **313**, 1929–35 (2006).
47. Sirota, M. *et al.* Discovery and preclinical validation of drug indications using compendia of public gene expression data. *Sci. Transl. Med.* **3**, 96ra77 (2011).
48. Corsello, S. M. *et al.* The Drug Repurposing Hub: a next-generation drug library and information resource. *Nat. Med.* **23**, 405–408 (2017).
49. Subramanian, A. *et al.* A Next Generation Connectivity Map: L1000 Platform and the First 1,000,000 Profiles. *Cell* **171**, 1437–1452.e17 (2017).
50. Cho, M. H. *et al.* A Genome-Wide Association Study of Emphysema and Airway Quantitative Imaging Phenotypes. *Am. J. Respir. Crit. Care Med.* **192**, 559–69 (2015).
51. MacArthur, J. *et al.* The new NHGRI-EBI Catalog of published genome-wide association studies (GWAS Catalog). *Nucleic Acids Res.* **45**, D896–D901 (2017).
52. Zheng, J. *et al.* LD Hub: a centralized database and web interface to perform LD score

- regression that maximizes the potential of summary level GWAS data for SNP heritability and genetic correlation analysis. *Bioinformatics* **33**, 272–279 (2017).
53. Pickrell, J. K. *et al.* Detection and interpretation of shared genetic influences on 42 human traits. *Nat. Genet.* **48**, 709–17 (2016).
 54. Demenais, F. *et al.* Multiancestry association study identifies new asthma risk loci that colocalize with immune-cell enhancer marks. *Nat. Genet.* **50**, 42–53 (2018).
 55. Fingerlin, T. E. *et al.* Genome-wide imputation study identifies novel HLA locus for pulmonary fibrosis and potential role for auto-immunity in fibrotic idiopathic interstitial pneumonia. *BMC Genet.* **17**, 74 (2016).
 56. Skronska-Wasek, W. *et al.* Reduced Frizzled Receptor 4 Expression Prevents WNT/ β -Catenin-driven Alveolar Lung Repair in Chronic Obstructive Pulmonary Disease. *Am. J. Respir. Crit. Care Med.* **196**, 172–185 (2017).
 57. Sakornsakolpat, P. *et al.* Integrative genomics identifies new genes associated with severe COPD and emphysema. *Respir. Res.* **19**, 46 (2018).
 58. Bui, D. S. *et al.* Childhood predictors of lung function trajectories and future COPD risk: a prospective cohort study from the first to the sixth decade of life. *Lancet. Respir. Med.* (2018). doi:10.1016/S2213-2600(18)30100-0
 59. McGeachie, M. J. *et al.* Patterns of Growth and Decline in Lung Function in Persistent Childhood Asthma. *N. Engl. J. Med.* **374**, 1842–1852 (2016).
 60. Ross, J. C. *et al.* Longitudinal Modeling of Lung Function Trajectories in Smokers with and without COPD. *Am. J. Respir. Crit. Care Med.* (2018). doi:10.1164/rccm.201707-1405OC
 61. Boucherat, O., Morissette, M. C., Provencher, S., Bonnet, S. & Maltais, F. Bridging Lung Development with Chronic Obstructive Pulmonary Disease. Relevance of Developmental Pathways in Chronic Obstructive Pulmonary Disease Pathogenesis. *Am. J. Respir. Crit. Care Med.* **193**, 362–75 (2016).
 62. Nelson, M. R. *et al.* The support of human genetic evidence for approved drug indications. *Nat. Genet.* **47**, 856–60 (2015).
 63. Miossec, P. & Kolls, J. K. Targeting IL-17 and TH17 cells in chronic inflammation. *Nat. Rev. Drug Discov.* **11**, 763–76 (2012).
 64. Mellett, M. *et al.* Orphan receptor IL-17RD tunes IL-17A signalling and is required for neutrophilia. *Nat. Commun.* **3**, 1119 (2012).
 65. O’Leary, N. A. *et al.* Reference sequence (RefSeq) database at NCBI: current status, taxonomic expansion, and functional annotation. *Nucleic Acids Res.* **44**, D733–45 (2016).
 66. Fagerberg, L. *et al.* Analysis of the human tissue-specific expression by genome-wide integration of transcriptomics and antibody-based proteomics. *Mol. Cell. Proteomics* **13**, 397–406 (2014).
 67. Saito, A., Ozaki, K., Fujiwara, T., Nakamura, Y. & Tanigami, A. Isolation and mapping of a human lung-specific gene, TSA1902, encoding a novel chitinase family member. *Gene* **239**, 325–31 (1999).
 68. Aminuddin, F. *et al.* Genetic association between human chitinases and lung function in COPD. *Hum. Genet.* **131**, 1105–14 (2012).
 69. Birben, E. *et al.* The effects of an insertion in the 5’UTR of the AMCase on gene expression and pulmonary functions. *Respir. Med.* **105**, 1160–9 (2011).
 70. Chatterjee, R., Batra, J., Das, S., Sharma, S. K. & Ghosh, B. Genetic association of acidic mammalian chitinase with atopic asthma and serum total IgE levels. *J. Allergy Clin.*

- Immunol.* **122**, 202–8, 208.e1–7 (2008).
71. Ober, C. & Chupp, G. L. The chitinase and chitinase-like proteins: a review of genetic and functional studies in asthma and immune-mediated diseases. *Curr. Opin. Allergy Clin. Immunol.* **9**, 401–8 (2009).
 72. Heinzmann, A. *et al.* Joint influences of Acidic-Mammalian-Chitinase with Interleukin-4 and Toll-like receptor-10 with Interleukin-13 in the genetics of asthma. *Pediatr. Allergy Immunol.* **21**, e679-86 (2010).
 73. Okawa, K. *et al.* Loss and Gain of Human Acidic Mammalian Chitinase Activity by Nonsynonymous SNPs. *Mol. Biol. Evol.* **33**, 3183–3193 (2016).
 74. Yang, J. *et al.* Rootletin, a novel coiled-coil protein, is a structural component of the ciliary rootlet. *J. Cell Biol.* **159**, 431–40 (2002).
 75. Gibson, M. A., Hughes, J. L., Fanning, J. C. & Cleary, E. G. The major antigen of elastin-associated microfibrils is a 31-kDa glycoprotein. *J. Biol. Chem.* **261**, 11429–36 (1986).
 76. Massaro, G. D. *et al.* Retinoic acid receptor-beta: an endogenous inhibitor of the perinatal formation of pulmonary alveoli. *Physiol. Genomics* **4**, 51–7 (2000).
 77. Markovics, J. A. *et al.* Interleukin-1beta induces increased transcriptional activation of the transforming growth factor-beta-activating integrin subunit beta8 through altering chromatin architecture. *J. Biol. Chem.* **286**, 36864–74 (2011).
 78. Kitamura, H. *et al.* Mouse and human lung fibroblasts regulate dendritic cell trafficking, airway inflammation, and fibrosis through integrin $\alpha\text{v}\beta\text{8}$ -mediated activation of TGF- β . *J. Clin. Invest.* **121**, 2863–75 (2011).
 79. Araya, J. *et al.* Squamous metaplasia amplifies pathologic epithelial-mesenchymal interactions in COPD patients. *J. Clin. Invest.* **117**, 3551–62 (2007).
 80. Zeltz, C. & Gullberg, D. The integrin-collagen connection - a glue for tissue repair? *J. Cell Sci.* **129**, 1284 (2016).
 81. Hall, N. G., Klenotic, P., Anand-Apte, B. & Apte, S. S. ADAMTSL-3/punctin-2, a novel glycoprotein in extracellular matrix related to the ADAMTS family of metalloproteases. *Matrix Biol.* **22**, 501–10 (2003).
 82. Apte, S. S. A disintegrin-like and metalloprotease (reprolysin-type) with thrombospondin type 1 motif (ADAMTS) superfamily: functions and mechanisms. *J. Biol. Chem.* **284**, 31493–7 (2009).
 83. Kutz, W. E. *et al.* ADAMTS10 protein interacts with fibrillin-1 and promotes its deposition in extracellular matrix of cultured fibroblasts. *J. Biol. Chem.* **286**, 17156–67 (2011).
 84. Gabriel, L. A. R. *et al.* ADAMTSL4, a secreted glycoprotein widely distributed in the eye, binds fibrillin-1 microfibrils and accelerates microfibril biogenesis. *Invest. Ophthalmol. Vis. Sci.* **53**, 461–9 (2012).
 85. Tsutsui, K. *et al.* ADAMTSL-6 is a novel extracellular matrix protein that binds to fibrillin-1 and promotes fibrillin-1 fibril formation. *J. Biol. Chem.* **285**, 4870–82 (2010).
 86. Ghosh, M. *et al.* Exhaustion of Airway Basal Progenitor Cells in Early and Established Chronic Obstructive Pulmonary Disease. *Am. J. Respir. Crit. Care Med.* **197**, 885–896 (2018).
 87. Crystal, R. G. Airway basal cells. The ‘smoking gun’ of chronic obstructive pulmonary disease. *Am. J. Respir. Crit. Care Med.* **190**, 1355–62 (2014).
 88. Giordano, R. J. *et al.* Targeted induction of lung endothelial cell apoptosis causes emphysema-like changes in the mouse. *J. Biol. Chem.* **283**, 29447–60 (2008).

89. Franks, T. J. *et al.* Resident cellular components of the human lung: current knowledge and goals for research on cell phenotyping and function. *Proc. Am. Thorac. Soc.* **5**, 763–6 (2008).
90. Boschetto, P. *et al.* Predominant emphysema phenotype in chronic obstructive pulmonary. *Eur. Respir. J.* **21**, 450–4 (2003).
91. Castaldi, P. J. *et al.* Cluster analysis in the COPDGene study identifies subtypes of smokers with distinct patterns of airway disease and emphysema. *Thorax* **69**, 415–22 (2014).
92. Cerveri, I. *et al.* The rapid FEV(1) decline in chronic obstructive pulmonary disease is associated with predominant emphysema: a longitudinal study. *COPD* **10**, 55–61 (2013).
93. Bonàs-Guarch, S. *et al.* Re-analysis of public genetic data reveals a rare X-chromosomal variant associated with type 2 diabetes. *Nat. Commun.* **9**, 321 (2018).
94. Dehghan, A. *et al.* Meta-analysis of genome-wide association studies in >80 000 subjects identifies multiple loci for C-reactive protein levels. *Circulation* **123**, 731–8 (2011).
95. Hersh, C. P. *et al.* Non-emphysematous chronic obstructive pulmonary disease is associated with diabetes mellitus. *BMC Pulm. Med.* **14**, 164 (2014).
96. Higami, Y. *et al.* Increased Epicardial Adipose Tissue Is Associated with the Airway Dominant Phenotype of Chronic Obstructive Pulmonary Disease. *PLoS One* **11**, e0148794 (2016).
97. Chung, K. F. & Barnes, P. J. Cytokines in asthma. *Thorax* **54**, 825–57 (1999).
98. Kroegel, C., Julius, P., Matthys, H., Virchow, J. C. & Luttmann, W. Endobronchial secretion of interleukin-13 following local allergen challenge in atopic asthma: relationship to interleukin-4 and eosinophil counts. *Eur. Respir. J.* **9**, 899–904 (1996).
99. Boutten, A. *et al.* Decreased expression of interleukin 13 in human lung emphysema. *Thorax* **59**, 850–4 (2004).
100. Washko, G. R. *et al.* Lung volumes and emphysema in smokers with interstitial lung abnormalities. *N. Engl. J. Med.* **364**, 897–906 (2011).
101. Chilosi, M., Poletti, V. & Rossi, A. The pathogenesis of COPD and IPF: distinct horns of the same devil? *Respir. Res.* **13**, 3 (2012).
102. Kulkarni, T., O'Reilly, P., Antony, V. B., Gaggar, A. & Thannickal, V. J. Matrix Remodeling in Pulmonary Fibrosis and Emphysema. *Am. J. Respir. Cell Mol. Biol.* **54**, 751–60 (2016).
103. Wan, M., Qin, J., Songyang, Z. & Liu, D. OB fold-containing protein 1 (OBFC1), a human homolog of yeast Stn1, associates with TPP1 and is implicated in telomere length regulation. *J. Biol. Chem.* **284**, 26725–31 (2009).
104. Albrecht, E. *et al.* Telomere length in circulating leukocytes is associated with lung function and disease. *Eur. Respir. J.* **43**, 983–92 (2014).
105. Armanios, M. Telomerase and idiopathic pulmonary fibrosis. *Mutat. Res.* **730**, 52–8 (2012).
106. Stanley, S. E. *et al.* Telomerase mutations in smokers with severe emphysema. *J. Clin. Invest.* **125**, 563–70 (2015).
107. Tinkelman, D. G., Price, D. B., Nordyke, R. J. & Halbert, R. J. Misdiagnosis of COPD and asthma in primary care patients 40 years of age and over. *J. Asthma* **43**, 75–80 (2006).
108. Foreman, M. G. *et al.* Alpha-1 Antitrypsin PiMZ Genotype Is Associated with Chronic Obstructive Pulmonary Disease in Two Racial Groups. *Ann. Am. Thorac. Soc.* **14**, 1280–1287 (2017).

109. Han, M. K. *et al.* Gender and chronic obstructive pulmonary disease: why it matters. *Am. J. Respir. Crit. Care Med.* **176**, 1179–84 (2007).

Figure legends

Figure 1 Study design

COPD, chronic obstructive pulmonary disease; FEV₁, force expiratory volume in one second; FVC, forced vital capacity. ARIC, Atherosclerosis Risk in Communities.

Figure 2 Manhattan plot

P-values are two-sided based on Wald statistics (35,735 cases and 222,076 controls) without multiple comparison adjustment. Loci are labeled with the closest gene to the lead variant.

Figure 3 Identification of target genes

(a) Overview of datasets used to identify target genes at genome-wide significant loci (b) Regional association plots at *ADAMTSL3* locus showing GWAS (top), chromatin interaction in lung tissue (middle) and expression quantitative trait loci (bottom). GWAS *P*-values are two-sided based on Wald statistics (35,735 cases and 222,076 controls). Expression quantitative trait loci (eQTL) *P*-values are two-sided based on *t* statistics (1,038 samples). *P*-values for Hi-C data were calculated using binomial distribution from spline-fitted and outlier-filtered distribution of contacts. All *P*-values were not adjusted for multiple comparison. GREx, gene-based association using gene expression; mQTL, colocalization with methylation quantitative trait loci; Cod., significant single variant or gene-based association tests for deleterious coding variants from exome data; Hi-C, significant chromatin interaction identified in human lung or the IMR90 cell line; DHS, overlap with DNase hypersensitivity sites; GSet, prioritized genes from DEPICT.

Figure 4 Effects on COPD-related and other phenotypes

(a) Heatmap of scaled computed tomography (CT) quantitative imaging associations with the 34 genome-wide significant variants (known and replicated novel associations) with at least nominal ($P < 0.05$) association with any CT imaging feature in COPD Gene non-Hispanic white participants. Cluster 1 variants are more associated with airway imaging features and Cluster 2 variants are more associated with emphysema imaging features. Variants are referred to by the closest gene. (b) Overlap of genome-wide significant loci of COPD and select traits from GWAS Catalog (c) Genome-wide overlapping results between COPD with pulmonary fibrosis (left) and asthma (right). PRM emphysema, emphysema quantified by parametric response mapping; UL, upper lobe of the lung; LL, lower lobe of the lung; Pi10, airway wall thickness calculated from regressing the square root of the airway wall area with the airway internal perimeter. CAD, coronary artery disease; BMD, bone mineral density.

Table 1 Meta-analysis results showing 35 loci novel for COPD and lung function

rsID	HGVS name	Closest gene	Locus	Risk/alt. allele	Risk allele frequency	UK Biobank			ICGC Cohorts			Overall meta-analysis			SpiroMeta FEV1		SpiroMeta FEV1/FVC	
						OR	95% CI	P value	OR	95% CI	P value	OR	95% CI	P value	Beta	P value	Beta	P value
rs72673419	NC_000001.10:g.60913143C>T	<i>Clorf87</i>	1p32.1	T/C	0.05	1.13	1.07-1.18	2.0E-06	1.19	1.08-1.31	2.9E-04	1.14	1.09-1.19	4.0E-09	-0.02	1.3E-01	-0.05	3.0E-04
rs629619	NC_000001.10:g.111738108C>T	<i>DENND2D</i>	1p13.3	T/C	0.20	1.08	1.05-1.11	7.5E-08	1.10	1.04-1.16	8.2E-04	1.08	1.06-1.11	2.9E-10	-0.01	4.6E-01	-0.02	9.3E-04
rs10929386	NC_000002.11:g.15906179C>T	<i>DDX1</i>	2p24.3	C/T	0.49	1.06	1.03-1.08	1.2E-06	1.07	1.03-1.12	1.8E-03	1.06	1.04-1.08	9.1E-09	-0.02	3.1E-06	-0.02	7.1E-06
rs62259026	NC_000003.11:g.57746515C>T	<i>SLMAP</i>	3p14.3	C/T	0.75	1.07	1.04-1.09	1.8E-06	1.07	1.02-1.12	3.8E-03	1.07	1.04-1.09	2.4E-08	-0.03	3.3E-05	-0.01	6.4E-02
rs4585380	NC_000004.11:g.75673363G>A	<i>BTC</i>	4q13.3	G/A	0.74	1.07	1.04-1.10	1.2E-07	1.06	1.02-1.11	8.1E-03	1.07	1.05-1.09	3.4E-09	-0.02	3.7E-04	-0.02	1.3E-03
rs12519165	NC_000005.9:g.170901586A>T	<i>FGF18</i>	5q35.1	A/T	0.38	1.08	1.05-1.10	2.7E-10	1.02	0.97-1.08	4.0E-01	1.07	1.05-1.09	1.1E-09	-0.02	6.5E-03	-0.03	2.4E-07
rs646695	NC_000006.11:g.140280398T>C	<i>CITED2</i>	6q24.1	C/T	0.24	1.07	1.05-1.10	3.0E-08	1.09	1.04-1.14	3.4E-04	1.08	1.05-1.10	4.6E-11	-0.02	5.6E-04	0.00	7.5E-01
rs2040732	NC_000007.13:g.20418134C>T	<i>ITGB8</i>	7p21.1	C/T	0.58	1.07	1.05-1.09	5.2E-09	1.03	0.99-1.07	1.7E-01	1.06	1.04-1.08	6.9E-09	-0.02	1.8E-03	-0.01	1.0E-02
rs1570221	NC_000010.10:g.105656874G>A	<i>STN1</i>	10q24.33	A/G	0.35	1.06	1.03-1.08	3.5E-06	1.07	1.03-1.12	1.4E-03	1.06	1.04-1.08	2.2E-08	-0.02	9.5E-04	-0.01	3.9E-02
rs4757118	NC_000011.9:g.13171236C>T	<i>ARNTL</i>	11p15.2	T/C	0.54	1.07	1.04-1.09	1.1E-08	1.04	1.00-1.08	7.3E-02	1.06	1.04-1.08	3.8E-09	-0.01	2.8E-01	-0.02	2.2E-03
rs9525927	NC_000013.10:g.44842503G>A	<i>SERP2</i>	13q14.11	G/A	0.19	1.07	1.04-1.10	2.9E-06	1.10	1.05-1.16	1.4E-04	1.08	1.05-1.10	2.8E-09	-0.02	2.2E-02	-0.02	2.2E-03
rs72731149	NC_000015.9:g.49984710G>C	<i>DTWD1</i>	15q21.2	G/C	0.91	1.12	1.07-1.17	8.9E-07	1.12	1.04-1.20	2.6E-03	1.12	1.08-1.16	8.3E-09	-0.05	7.9E-07	-0.03	9.0E-04
rs10152300	NC_000015.9:g.84392907G>A	<i>ADAMTSL3</i>	15q25.2	G/A	0.23	1.09	1.06-1.11	2.4E-10	1.08	1.02-1.13	4.7E-03	1.08	1.06-1.11	4.2E-12	-0.01	6.4E-02	-0.02	1.5E-03
rs955277	NC_000002.11:g.9290357C>T	<i>ASAP2</i>	2p25.1	T/C	0.61	1.08	1.05-1.10	2.7E-10	1.04	0.99-1.08	8.6E-02	1.07	1.05-1.09	1.9E-10	0.00	9.6E-01	-0.01	3.3E-02
rs12466981	NC_000002.11:g.42433247C>T	<i>EML4</i>	2p21	C/T	0.73	1.06	1.03-1.08	8.1E-06	1.08	1.03-1.13	1.2E-03	1.06	1.04-1.09	4.9E-08	-0.01	4.4E-02	-0.01	6.4E-02
rs2442776	NC_000003.11:g.11640601G>A	<i>VGLL4</i>	3p25.3	G/A	0.15	1.09	1.06-1.13	5.7E-08	1.10	1.04-1.16	8.9E-04	1.09	1.06-1.12	2.0E-10	-0.01	6.4E-02	-0.01	1.3E-01
rs4093840	NC_000003.11:g.123077042T>A	<i>ADCY5</i>	3q21.1	A/T	0.47	1.07	1.05-1.09	1.6E-09	1.04	1.00-1.09	4.8E-02	1.06	1.04-1.08	3.9E-10	-0.01	8.5E-02	-0.00	3.8E-01
rs62375246	NC_000005.9:g.132439010T>A	<i>HSPA4</i>	5q31.1	A/T	0.26	1.08	1.05-1.10	9.6E-09	1.03	0.98-1.08	2.7E-01	1.06	1.04-1.09	2.2E-08	-0.02	1.3E-02	-0.01	2.2E-01
rs979453	NC_000005.9:g.150595073A>G	<i>CCDC69</i>	5q33.1	G/A	0.34	1.07	1.05-1.10	1.6E-09	1.02	0.97-1.06	5.1E-01	1.06	1.04-1.08	1.4E-08	-0.01	7.2E-02	-0.00	6.4E-01
rs1334576	NC_000006.11:g.7211818G>A	<i>RREB1</i>	6p24.3	A/G	0.42	1.07	1.05-1.09	4.2E-09	1.02	0.99-1.06	2.2E-01	1.06	1.04-1.08	1.2E-08	0.00	6.9E-01	-0.01	2.9E-02
rs9350191	NC_000006.11:g.19842661C>T	<i>ID4</i>	6p22.3	T/C	0.85	1.11	1.08-1.15	6.2E-12	1.14	1.05-1.23	1.9E-03	1.12	1.09-1.15	5.1E-14	-0.02	4.9E-02	-0.01	1.5E-01
rs2284174	NC_000006.11:g.30713580T>C	<i>IER3</i>	6p21.33	C/T	0.22	1.12	1.10-1.15	3.4E-19	1.12	1.05-1.21	1.5E-03	1.12	1.10-1.15	2.1E-21	-0.01	5.2E-02	-0.02	3.0E-02
rs674621	NC_000006.11:g.117257018T>C	<i>RFX6</i>	6q22.1	C/T	0.32	1.06	1.03-1.08	1.3E-06	1.07	1.03-1.12	1.4E-03	1.06	1.04-1.08	7.6E-09	-0.01	3.6E-02	-0.01	6.9E-02
rs9329170	NC_000008.10:g.8697658C>G	<i>MFHAS1</i>	8p23.1	C/G	0.86	1.10	1.06-1.14	2.0E-08	1.09	1.03-1.15	4.9E-03	1.10	1.07-1.13	3.6E-10	-0.02	4.6E-02	-0.01	6.5E-02
rs10760580	NC_000009.11:g.101661650G>A	<i>COL15A1</i>	9q22.33	G/A	0.71	1.08	1.06-1.11	1.6E-10	1.04	0.99-1.09	1.1E-01	1.07	1.05-1.10	1.2E-10	-0.02	1.5E-02	-0.02	1.4E-02
rs8044657	NC_000016.9:g.58022625G>A	<i>TEPP</i>	16q21	G/A	0.90	1.12	1.07-1.16	1.7E-07	1.09	1.01-1.17	1.8E-02	1.11	1.07-1.15	1.1E-08	-0.02	9.9E-02	-0.02	2.8E-02
rs62065216	NC_000017.10:g.38218773G>A	<i>THRA</i>	17q21.1	A/G	0.42	1.06	1.04-1.09	1.2E-07	1.06	1.01-1.10	2.2E-02	1.06	1.04-1.08	8.1E-09	-0.01	7.8E-02	-0.00	8.0E-01
rs4660861	NC_000001.10:g.45946636G>T	<i>TESK2</i>	1p34.1	G/T	0.57	1.05	1.03-1.08	7.2E-06	1.07	1.03-1.12	1.2E-03	1.06	1.04-1.08	4.4E-08	-0.01	3.0E-01	-0.00	4.1E-01
rs7650602	NC_000003.11:g.141147414T>C	<i>ZBTB38</i>	3q23	C/T	0.45	1.07	1.04-1.09	6.7E-09	1.01	0.97-1.06	5.1E-01	1.06	1.04-1.08	4.9E-08	0.00	8.4E-01	-0.01	3.2E-01
rs34651	NC_000005.9:g.72144005C>T	<i>TNPO1</i>	5q13.2	C/T	0.08	1.10	1.06-1.15	7.5E-07	1.12	1.02-1.22	1.2E-02	1.11	1.07-1.15	3.0E-08	-0.00	7.6E-01	0.00	7.5E-01
rs798565	NC_000007.13:g.2752152G>A	<i>AMZ1</i>	7p22.3	G/A	0.71	1.09	1.06-1.11	2.8E-11	1.00	0.95-1.05	8.8E-01	1.07	1.04-1.09	3.9E-09	-0.01	1.2E-01	-0.00	6.1E-01

rsID	HGVS name	Closest gene	Locus	Risk/alt. allele	Risk allele frequency	UK Biobank			ICGC Cohorts			Overall meta-analysis			SpiroMeta FEV1		SpiroMeta FEV1/FVC	
						OR	95% CI	P value	OR	95% CI	P value	OR	95% CI	P value	Beta	P value	Beta	P value
rs7866939	NC_000009.11:g.85126163T>C	<i>RASEF</i>	9q21.32	C/T	0.33	1.06	1.03-1.08	1.3E-06	1.07	1.02-1.12	3.8E-03	1.06	1.04-1.08	1.7E-08	-0.01	2.5E-01	-0.01	1.1E-01
rs7958945	NC_000012.11:g.115947901A>G	<i>MED13L</i>	12q24.21	G/A	0.36	1.06	1.04-1.09	1.0E-07	1.07	1.02-1.11	2.8E-03	1.06	1.04-1.09	1.0E-09	-0.01	1.5E-01	-0.00	6.2E-01
rs72626215	NC_000019.9:g.46294136G>A	<i>DMWD</i>	19q13.32	G/A	0.73	1.06	1.04-1.09	1.7E-06	1.11	1.05-1.17	7.3E-05	1.07	1.05-1.10	1.7E-09	0.00	4.8E-01	-0.01	1.2E-01
rs73158393	NC_000022.10:g.33335386C>G	<i>SYN3</i>	22q12.3	C/G	0.74	1.06	1.04-1.09	1.1E-06	1.09	1.03-1.14	1.4E-03	1.07	1.05-1.09	7.7E-09	-0.00	7.7E-01	-0.01	3.3E-01

CI, confidence interval; OR, odds ratio; ICGC, International COPD Genetics Consortium; HGVS, Human Genome Variation Society. This table shows association statistics in UK Biobank (21,081 cases and 179,711 controls), ICGC cohorts (14,654 cases and 42,365 controls), the overall meta-analysis (35,735 cases and 222,076 controls), and SpiroMeta studies (FEV1 and FEV1/FVC; n=79,055). P values are two-sided based on Wald statistics (COPD) and t statistics (FEV1 and FEV1/FVC) without multiple comparison adjustment. White = Significant in SpiroMeta using Bonferroni correction for novel loci (one-sided $P < 0.05/35$); Grey = Nominally significant in SpiroMeta (one-sided $P < 0.05$), Dark grey = not significant (directionally consistent only)

URLs

HGNC database of human gene names, <https://www.genenames.org/>; The Drug Repurposing Hub, <https://clue.io/repurposing>; The Query, <https://clue.io/query>; Human Genome Region MHC by Genome Reference Consortium, <https://www.ncbi.nlm.nih.gov/grc/human/regions/MHC?asm=GRCh37.p13>; EMBL-EBI GWAS Catalog, <https://www.ebi.ac.uk/gwas/>; LungMAP, <https://www.lungmap.net/>.

Methods

Study populations

The UK Biobank is a population-based cohort consisting of 502,682 individuals⁸. To determine lung function, we used measures of forced expiratory volume in 1 second (FEV₁) and forced vital capacity (FVC) derived from the spirometry blow volume-time series data, subjected to additional quality control based on ATS/ERS criteria¹¹⁰ (**Supplementary Note**). As in our previous study⁵, we defined COPD using pre-bronchodilator spirometry according to modified Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria for moderate to very severe airflow limitation⁹: FEV₁ less than 80% of predicted value (using reference equations from Hankinson et al.¹¹¹), and the ratio between FEV₁ and FVC less than 0.7. Consistent with our previous analyses and enrollment criteria for COPD case-control datasets¹¹², we did not exclude individuals based on self-reported asthma. Genotyping was performed using Axiom UK BiLEVE array and Axiom Biobank array (Affymetrix, Santa Clara, California, USA) and imputed to the Haplotype Reference Consortium (HRC) version 1.1 panel¹¹³.

We invited participants in the prior International COPD Genetics Consortium (ICGC) COPD genome-wide association study to provide case-control association results (with the exception of the 1958 British Birth Cohort, to avoid overlapping samples with the replication sample). ICGC cohorts performed case-control association analysis based on pre-bronchodilator measurements of FEV₁ and FEV₁/FVC, and cases were identified using modified GOLD criteria, as above. Studies were imputed to 1000 Genomes reference panels. Detailed cohort descriptions and cohort-specific methods have been previously published⁵ (**Supplementary Note**). All studies comply to all relevant ethical regulations. Ethical/regulatory boards approved the study protocol for each study (**Supplementary Note**). We obtained informed consent from all participating individuals.

Based on the strong genetic overlap of lung function and COPD⁵, we performed lookups of select significant variants for FEV₁ and FEV₁/FVC in the SpiroMeta consortium meta-analysis²¹. Briefly, SpiroMeta comprised a total of 79,055 individuals from 22 studies imputed to either the 1000 Genomes Project Phase 1 reference panel (13 studies) or the HRC (9 studies). Each study performed linear regression adjusting for age, age², sex, and height, using rank-based inverse normal transforms, adjusting for population substructure using principal components or linear mixed models, and performing separate analyses for ever- and never- smokers or using a covariate for smoking (for studies of related subjects). Genomic control was applied to individual studies, and results were combined using a fixed-effects meta-analysis²¹.

Genome-wide association analysis

In UK Biobank, we performed logistic regression of COPD, adjusting for age, sex, genotyping array, smoking pack-years, ever smoking status, and principal components of genetic ancestry. Association analysis was done using PLINK 2.0 alpha¹¹⁴ (downloaded on December 11, 2017)

with Firth-fallback settings, using Firth regression when quasi-complete separation or regular-logistic-regression convergence failure occurred. We performed a fixed-effects meta-analysis of all ICGC cohorts and UK Biobank using METAL (version 2010-08-01)¹¹⁵. We assessed population substructure and cryptic relatedness by linkage disequilibrium (LD) score regression intercept¹⁰. We defined a genetic locus using a 2-Mb window (+/-1 Mb) around a lead variant, with conditional analyses as described below.

To maximize our power to identify existing and discover new loci, we examined all loci at the genome-wide significance value of $P < 5 \times 10^{-8}$. We first characterized loci as being previously described (evidence of prior association with lung function^{12-20,116,117} or COPD^{5,11,118}) or novel. We defined previously reported signals if they were in the same LD block in Europeans¹¹⁹ and in at least moderate LD ($r^2 \geq 0.2$). For novel loci we attempted replication through association of each lead variant with either FEV₁ or FEV₁/FVC ratio in SpiroMeta, using one-sided P -values with Bonferroni correction for the number of novel loci examined. Novel loci failing to meet a Bonferroni-corrected P -value were assessed for nominal significance (one-sided $P < 0.05$) or directional consistence with FEV₁ and FEV₁/FVC ratio in SpiroMeta.

Cigarette smoking is the major environmental risk factor for COPD and genetic loci associated with cigarette smoking have been reported^{5,120}. While we adjusted for cigarette smoking in our analysis, we further examined these effects by additionally testing for association of each locus with cigarette smoking and by looking at two separate analyses of ever- and never- smokers in UK Biobank. We tested for sex-specific genetic effects of genome-wide significant variants via a stratified analysis and interaction testing, using a 5% Bonferroni-corrected threshold to determine significance (**Supplementary Note**).

Identification of independent associations at genome-wide significant loci

We identified specific independent associations at genome-wide significant loci using GCTA-COJO²². This method utilizes an approximate conditional and joint analysis approach requiring summary statistics and representative LD information. As the UK Biobank provided the predominant sample, we used 10,000 randomly drawn unrelated individuals from this discovery dataset as a LD reference sample. We scaled genome-wide significance to a 2-Mb region, resulting in a locus-wide significant threshold of 8×10^{-5} , or 2×10^{-6} for variants in the major histocompatibility complex (MHC) region (chr6:28477797-33448354 in hg19). We created regional association plots via LocusZoom using 1000 Genomes EUR reference data¹²¹ (Nov2014 release).

Identification and prioritization of tissues and cell types, candidate variants, genes, and pathways

Identification of enriched tissues and specific cell types

We used LD Score Regression (LDSC) to estimate the enrichment of functional annotations²⁶ and specifically expressed gene regions³¹ on disease heritability. We utilized LDSC baseline models (e.g., conserved region, promoter flanking region), tissue-specific annotations from the Roadmap Epigenomics Program³¹, integrated tissue annotations from GenoSkyline²⁵, and cell type-specific chromatin accessibility data²⁷ (ATAC-Seq). We used four single-cell gene expression (RNA-Seq) datasets to identify specific cell types (**Supplementary Note**), including 1) lung epithelial cells from normal and pulmonary fibrosis human lung²⁸ (Gene Expression Omnibus [GEO] accession GSE86618), 2) human induced pluripotent stem cells (iPSCs)-derived putative alveolar type 2 cells²⁹ (GSE96642), 3) mouse lungs at embryonic day 18.5 (E18.5) and 4) postnatal day 1 (P1) by Whitsett et al. (unpublished, available at LungMAP³⁰). We also used

SNPsea³² to identify enriched cell types in genome-wide significant loci (**Supplementary Note**). We reported only estimates of coefficients and *P*-values for the Roadmap annotations and gene expression datasets, as these analyses used $-h^2$ -cts, which does not report fold enrichment.

Fine-mapping of independent association signals at genome-wide significant loci

We used Bayesian fine-mapping at each locus to identify the credible set: the set of variants with a 99% probability of containing a causal variant. Briefly, for each genome-wide significant loci we calculated approximate Bayes factors³³ of association. We then selected variants in each locus, so that their cumulative posterior probability was equal or greater than 0.99 using an unscaled variance. At loci with multiple independent associations, we used statistics from approximate conditional analysis with GCTA software on each index variant adjusting for other independent variants in the loci. Otherwise, we used unconditioned statistics from our meta-analysis. Details on characterization of variant effects are summarized in the **Supplementary Note**.

Identification of target genes

We used several computational approaches with corresponding available datasets to identify target genes in genome-wide significant loci. We used two methods that utilized gene expression data: 1) S-PrediXcan and 2) DEPICT. We used S-PrediXcan³⁷ to identify genes with genetically regulated expression associated with COPD. We used data from the Lung-eQTL consortium³⁸ (1,038 lung tissue samples) as an expression quantitative trait loci (eQTL) and gene expression reference database. S-PrediXcan tests for association between a trait and imputed gene expression using summary statistics. Here, we performed S-PrediXcan using models for protein-coding genes +/- 1 Mb from top-associated variants at genome-wide significant loci. We used DEPICT (Data-driven Expression Prioritized Integration for Complex Traits)⁴² to prioritize genes from 'reconstituted' gene sets.

We also used additional information on gene regulation, including epigenetic data: 1) regulatory fine mapping, 2) methylation quantitative trait loci (mQTL), and 3) chromosome conformation capture. We used regulatory fine mapping (regfm⁴¹) to overlap 99% credible interval (CI) variants at each GWAS locus with open chromatin regions based on DNase hypersensitivity sites (DHS). DHS cluster accessibility state was then associated with gene expression levels (for 13,771 genes) from 22 tissues in the Roadmap Epigenomics Project⁴¹. Using both the 99% CI and DHS overlap, as well as the DHS state and transcript level association, regfm calculates a posterior probability of association of each gene +/- 1 Mb of the lead SNP at each GWAS locus. We also searched for overlapping mQTL data from lung tissue, as recently described³⁹. To determine whether these signals co-localized (rather than being related due to linkage disequilibrium), we performed colocalization analysis between our GWAS and mQTL in genome-wide significant loci using eCAVIAR¹²² (eQTL and GWAS CAusal Variants Identification in Associated Regions, **Supplementary Note**). We also sought information from publicly available chromosome conformation capture data⁴⁰. We queried association statistics of chromatin contact (i.e., long range chromatin interactions) between top associated variants and gene promoters nearby in a lung (fetal lung fibroblast cell line (IMR90) and human lung tissue⁴⁰) using HUGIn¹²³ (Hi-C Unifying Genomic Interrogator). We retained only the strongest associations (i.e., smallest *P*-value) for each cell line/primary cell in the analysis.

Finally, we searched for signals from deleterious variants by querying consequences of variants within 99% credible sets containing fewer than 50 variants (**Supplementary Note**). We also searched for rare coding variants, based on exome sequencing results in the COPDGene, Boston Early-Onset COPD (BEOCOPD), and International COPD Genetics Network (ICGN) studies, as

previously described⁴³. In brief, we performed exome sequencing on 485 severe COPD cases and 504 smoking resistant controls from the COPDGene study and 1,554 subjects ascertained through 631 probands with severe COPD from the BEOCOPD and the ICGN study. Details on statistical tests for single-variant and gene-based analyses are summarized in the **Supplementary Note**.

For each dataset described above, we used Bonferroni-corrected P -values, or a fixed posterior probability threshold to determine target genes at each locus. We reported protein-coding genes ± 1 Mb from a top associated variant. We restricted our search to genes from the GRCh37 server in biomaRt¹²⁴ with updated HUGO Gene Nomenclature Committee (HGNC) names (downloaded from HGNC database of human gene names on June 7, 2018). For each locus, we used a 5% Bonferroni-corrected threshold (i.e., $P < 0.05$ divided by number of genes at that locus) to determine significance for 4 data types: gene expression data, chromatin conformation capture data, co-regulation of gene expression, and exome sequencing results. For two remaining datasets, we used a fixed posterior probability (of gene association with a GWAS locus) threshold of 0.1 for regfm and eCAVIAR. We considered genes that were implicated by gene expression or ≥ 2 combination of other datasets (e.g., methylation and chromatin conformation capture data) as target genes.

Identification of pathways

To identify enriched pathways in COPD-associated loci, we performed gene-set enrichment analysis using the “reconstituted” genes sets from DEPICT, as described above⁴². We defined significant gene sets using false discovery rate (FDR) $< 5\%$.

Effects on COPD-related and other phenotypes

COPD is a complex and heterogeneous disorder, comprised of different biologic processes and specific phenotypic effects. In addition, many loci discovered by GWAS have pleiotropic effects. To identify these effects, we performed analyses of a) identification of overlapping genetic loci between related disorders (asthma and pulmonary fibrosis) b) genetic association studies of our genome-wide significant findings using COPD-related phenotypes, including a cluster analysis to identify groups of variants that may be acting via similar mechanisms; c) look up of top variants in prior COPD-related quantitative computed tomography (CT) imaging feature GWAS, d) look up of associations with other diseases/traits using GWAS Catalog, and e) estimate the genetic correlation between COPD and other diseases/traits.

To identify overlapping loci between COPD and other respiratory disorders, we used gwas-pw⁵³ to perform pairwise analysis of GWAS. This method searches for shared genomic segments¹¹⁹ using adaptive significance threshold, allowing detection of sub genome-wide significant loci. We identified shared segments or variants using posterior probability of colocalization greater than 0.7⁵³. We obtained GWAS summary statistics from previous studies of pulmonary fibrosis⁵⁵ and asthma in Europeans⁵⁴. For the overlap analysis of COPD with asthma, we examined the influence of the inclusion of individuals with self-reported asthma on both the overlap of discrete GWAS loci (using gwas-pw) and genome-wide genetic correlation (using LD score regression) by performing these analyses in the meta-analysis of ICGC studies and the UK Biobank (with individuals with asthma removed from cases in the latter). To assess heterogeneous effects of COPD susceptibility loci on COPD-related features (phenotypes), we evaluated associations of our genome-wide significant SNPs with 121 detailed phenotypes (e.g., lung function, computed tomography-derived metrics, biomarkers, and comorbidities) available in 6,760 COPDGene non-Hispanic whites. We calculated Z-scores for each SNP-phenotype combination relative to the COPD risk allele to create a SNP by phenotype Z-score matrix. We tested each COPD-related

phenotype with at least one nominally significant association with one of our genome-wide significant COPD SNPs, leaving us with 107 phenotypes. We then oriented all Z-scores to be positive (based on sign of median Z score) in association with each phenotype to avoid clustering based on direction of association. To avoid clustering phenotypes only by strength of association with SNPs, we scaled Z-scores within each phenotype by subtracting mean Z-scores and dividing by the standard deviation of Z-scores within each phenotype. We then scaled Z-scores across SNPs to circumvent clustering of SNPs according only to relative strength of association with phenotypes. We then performed hierarchical clustering of the scaled Z-scores of associations between SNPs and phenotypes to identify clusters of SNPs and phenotypes for all 107 phenotypes as well as in the subset of 26 quantitative imaging phenotypes. We performed the clustering of variants both in the set of all genome-wide significant variants in discovery as well as in the subset of known variants plus novel variants meeting a strict Bonferroni threshold in SpiroMeta replication (**Supplementary Note**). We further examined top variant associations with COPD-related traits through a look-up of top variants in a prior GWAS of 12,031 subjects with quantitative emphysema and airway CT features⁵⁰. To examine overlap of our COPD results with other traits, we downloaded genome-wide significant associations from the GWAS Catalog⁵¹ ($P < 5 \times 10^{-8}$; downloaded on April 10, 2018). Between a pair of COPD- and trait-associated variants within the same LD block in Europeans¹¹⁹, we computed the LD using the European ancestry panel¹²⁵ and considered the overlap if variants were in at least in moderate LD ($r^2 \geq 0.2$). We estimated genetic correlation between COPD and other diseases/traits using a web engine for LDSC, LD Hub⁵². We assessed the results using a 5% Bonferroni-corrected significance level.

Identification of drug targets

We queried our target genes using the Drug Repurposing Hub⁴⁸. This resource contains comprehensive annotations of launched drugs, drugs in phases 1-3 of clinical development, previously approved and preclinical or tool compounds, curated using publicly available sources (e.g., ChEMBL and Drugbank) and proprietary sources. We performed drug-gene expression similarity analysis⁴⁹ (the Query) using a ranked gene set from a gene-based association test³⁷ (**Supplementary Note**).

Reporting Summary

We provide further information on research design in the **Life Sciences Reporting Summary** linked to this article.

Data availability statement

The genome-wide association summary statistics are available at the database of Genotypes and Phenotypes (dbGaP) under accession phs000179.v5.p2 and via the UK Biobank. Derived phenotypic data for COPD case control status is also available in the UK Biobank.

References (Methods-only)

110. Miller, M. R. *et al.* Standardisation of spirometry. *Eur. Respir. J.* **26**, 319–38 (2005).
111. Hankinson, J. L., Odencrantz, J. R. & Fedan, K. B. Spirometric reference values from a sample of the general U.S. population. *Am. J. Respir. Crit. Care Med.* **159**, 179–87 (1999).
112. Regan, E. A. *et al.* Genetic epidemiology of COPD (COPDGene) study design. *COPD* **7**, 32–43 (2010).
113. McCarthy, S. *et al.* A reference panel of 64,976 haplotypes for genotype imputation. *Nat.*

- Genet.* **48**, 1279–83 (2016).
114. Chang, C. C. *et al.* Second-generation PLINK: rising to the challenge of larger and richer datasets. *Gigascience* **4**, 7 (2015).
 115. Willer, C. J., Li, Y. & Abecasis, G. R. METAL: fast and efficient meta-analysis of genomewide association scans. *Bioinformatics* **26**, 2190–2191 (2010).
 116. Lutz, S. M. *et al.* A genome-wide association study identifies risk loci for spirometric measures among smokers of European and African ancestry. *BMC Genet.* **16**, 138 (2015).
 117. Loth, D. W. *et al.* Genome-wide association analysis identifies six new loci associated with forced vital capacity. *Nat Genet* **46**, 669–677 (2014).
 118. Hobbs, B. D. *et al.* Exome Array Analysis Identifies a Common Variant in IL27 Associated with Chronic Obstructive Pulmonary Disease. *Am J Respir Crit Care Med* **194**, 48–57 (2016).
 119. Berisa, T. & Pickrell, J. K. Approximately independent linkage disequilibrium blocks in human populations. *Bioinformatics* **32**, 283–5 (2016).
 120. Consortium, T. and G. & Tobacco and Genetics Consortium. Genome-wide meta-analyses identify multiple loci associated with smoking behavior. *Nat. Genet.* **42**, 441–7 (2010).
 121. Pruim, R. J. *et al.* LocusZoom: regional visualization of genome-wide association scan results. *Bioinformatics* **26**, 2336–7 (2010).
 122. Hormozdiari, F. *et al.* Colocalization of GWAS and eQTL Signals Detects Target Genes. *Am. J. Hum. Genet.* **99**, 1245–1260 (2016).
 123. Martin, J. S. *et al.* HUGIn: Hi-C Unifying Genomic Interrogator. *Bioinformatics* **33**, 3793–3795 (2017).
 124. Durinck, S., Spellman, P. T., Birney, E. & Huber, W. Mapping identifiers for the integration of genomic datasets with the R/Bioconductor package biomaRt. *Nat. Protoc.* **4**, 1184–91 (2009).
 125. Machiela, M. J. & Chanock, S. J. LDlink: a web-based application for exploring population-specific haplotype structure and linking correlated alleles of possible functional variants. *Bioinformatics* **31**, 3555–7 (2015).

Full author list

The SpiroMeta Consortium:

Nick Shrine⁵, Anna L Guyatt⁵, Chiara Batini⁵, Jing Hua Zhao⁵³, Matthias Wielscher⁵⁴, Understanding Society Scientific Group⁵⁵, Stefan Weiss⁵⁶, Katherine A Kentistou^{57,58}, James P Cook⁵⁹, Jennie Hui^{60,61,62,63}, Stefan Karrasch^{64,65,66}, Medea Imboden^{67,68}, Sarah E Harris^{69,70}, Jonathan Marten⁷¹, Stefan Enroth⁷², Shona M Kerr⁷¹, Ida Surakka^{73,74}, Veronique Vitart⁷¹, Terho Lehtimäki⁷⁵, Ralf Ewert⁷⁶, Christian Gieger⁷⁷, Georg Homuth⁵⁶, Peter K Joshi⁵⁷, Claudia Langenberg⁷⁸, Lars Lind⁷⁹, Jian'an Luan⁷⁸, Anubha Mahajan⁸⁰, Alison Murray⁸¹, David J Porteous^{69,70}, Rajesh Rawal^{77,82}, Blair H Smith⁸³, Paul RHJ Timmers⁵⁷, Olli T Raitakari^{84,85}, Mika Kähönen⁸⁶, Ozren Polasek^{87,57}, Ulf Gyllensten⁷², Igor Rudan⁵⁷, Ian J Deary^{69,88}, Nicole M Probst-Hensch^{67,68}, Holger Schulz^{64,66}, Alan L James^{60,89,90}, James F Wilson^{57,71}, Beate Stubbe⁷⁶, Eleftheria Zeggini^{91,92}, Marjo-Riitta Jarvelin^{93,94,95,54,96}, Nick Wareham⁷⁸, Caroline Hayward⁷¹, Andrew P Morris^{59,80}, David P Strachan⁴¹, Ian P Hall^{28,29}, Martin D Tobin^{5,49}, Louise V Wain^{5,49}

53 Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK

54 Department of Epidemiology and Biostatistics, MRC–PHE Centre for Environment & Health, School of Public Health, Imperial College London, London, UK

55 A list of contributors can be found in the Supplementary Note

56 Interfaculty Institute for Genetics and Functional Genomics, Department of Functional Genomics, University Medicine Greifswald, Greifswald, Germany

57 Centre for Global Health Research, Usher Institute for Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, UK

58 Centre for Cardiovascular Sciences, Queen’s Medical Research Institute, University of Edinburgh, Edinburgh, UK

59 Department of Biostatistics, University of Liverpool, Liverpool, UK

60 Busselton Population Medical Research Institute, Sir Charles Gairdner Hospital, Nedlands WA, Australia

61 School of Population Health, The University of Western Australia, Crawley WA, Australia

62 PathWest Laboratory Medicine of WA, Sir Charles Gairdner Hospital, Crawley WA, Australia

63 School of Pathology and Laboratory Medicine, The University of Western Australia, Crawley WA, Australia

64 Institute of Epidemiology, Helmholtz Zentrum Muenchen – German Research Center for Environmental Health, Neuherberg, Germany

65 Institute and Outpatient Clinic for Occupational, Social and Environmental Medicine, Ludwig-Maximilians-Universität, Munich, Germany

66 Comprehensive Pneumology Center Munich (CPC-M), Member of the German Center for Lung Research (DZL), Munich, Germany

67 Swiss Tropical and Public Health Institute, Basel, Switzerland

68 University of Basel, Switzerland

69 Centre for Cognitive Ageing and Cognitive Epidemiology, University of Edinburgh, Edinburgh, UK

70 Centre for Genomic and Experimental Medicine, Institute of Genetics & Molecular Medicine, University of Edinburgh, Western General Hospital, Edinburgh, UK

71 Medical Research Council Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK

72 Department of Immunology, Genetics and Pathology, Uppsala Universitet, Science for Life Laboratory, Uppsala, Sweden

73 Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland

74 The National Institute for Health and Welfare (THL), Helsinki, Finland

75 Department of Clinical Chemistry, Fimlab Laboratories, and Finnish Cardiovascular Research Center - Tampere, Faculty of Medicine and Life Sciences, University of Tampere, Tampere, Finland

76 Department of Internal Medicine B - Cardiology, Intensive Care, Pulmonary Medicine and Infectious Diseases, University Medicine Greifswald, Greifswald, Germany

77 Research Unit of Molecular Epidemiology, Institute of Epidemiology, Helmholtz Zentrum Muenchen – German Research Center for Environmental Health, Neuherberg, Germany

78 MRC Epidemiology Unit, University of Cambridge School of Clinical Medicine, Cambridge, UK

79 Department of Medical Sciences, Cardiovascular Epidemiology, Uppsala University, Uppsala, Sweden

80 Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK
81 The Institute of Medical Sciences, Aberdeen Biomedical Imaging Centre, University of Aberdeen, Aberdeen, UK
82 Institute of Epidemiology and Social Medicine, University of Münster, Münster, Germany
83 Division of Population Health and Genomics, Ninewells Hospital and Medical School, University of Dundee, Dundee, UK
84 Department of Clinical Physiology and Nuclear Medicine, Turku University Hospital, Turku, Finland
85 Research Centre of Applied and Preventive Cardiovascular Medicine, University of Turku, Turku, Finland
86 Department of Clinical Physiology, Tampere University Hospital, and Finnish Cardiovascular Research Center - Tampere, Faculty of Medicine and Life Sciences, University of Tampere, Tampere, Finland
87 University of Split School of Medicine, Split, Croatia
88 Department of Psychology, University of Edinburgh, Edinburgh, UK
89 Department of Pulmonary Physiology and Sleep Medicine, Sir Charles Gairdner Hospital, Nedlands WA, Australia
90 School of Medicine and Pharmacology, The University of Western Australia, Crawley, Australia
91 Wellcome Sanger Institute, Hinxton, UK
92 Institute of Translational Genomics, Helmholtz Zentrum Muenchen – German Research Center for Environmental Health, Neuherberg, Germany
93 Center for Life Course Health Research, Faculty of Medicine, University of Oulu, Oulun yliopisto, Finland
94 Biocenter Oulu, University of Oulu, Finland
95 Unit of Primary Health Care, Oulu University Hospital, OYS, Oulu, Finland
96 Department of Life Sciences, College of Health and Life Sciences, Brunel University London, Uxbridge, UK

The International COPD Genetics Consortium:

Alvar Agusti⁹⁷, Wayne Anderson⁹⁸, Nawar Bakerly^{99,100}, Per Bakke¹⁴, Robert Bals¹⁰¹, Kathleen C. Barnes³⁷, R Graham Barr¹⁵, Terri H. Beaty¹⁶, Eugene R. Bleecker¹², H. Marika Boezen^{22,23}, Yohan Bossé^{4,45}, Russell Bowler²¹, Christopher Brightling^{102,49}, Marleen de Bruijne^{103,104}, Peter J. Castaldi¹, Bartolome Celli²⁴, Michael H. Cho^{1,24}, Harvey O. Coxson¹⁰⁵, James D. Crapo²¹, Ron Crystal¹⁰⁶, Pim de Jong¹⁰⁷, Asger Dirksen¹⁰⁸, Jennifer Dy¹⁰⁹, Marilyn Foreman¹¹⁰, Judith Garcia-Aymerich^{111,112,113}, Pierre Gevenois¹¹⁴, Soumitra Ghosh⁴², Hester Gietema¹¹⁵, Amund Gulsvik¹⁴, Ian P. Hall^{28,29}, Nadia Hansel¹¹⁶, Craig P. Hersh^{1,24}, Brian D. Hobbs^{1,24}, Eric Hoffman¹¹⁷, Noor Kalsheker¹¹⁸, Hans-Ulrich Kauczor¹¹⁹, Woo Jin Kim³¹, Deog Kyeom Kim⁹, Tarja Laitinen¹²⁰, Diether Lambrechts^{121,122}, Sang-Do Lee¹²³, Augusto A. Litonjua¹²⁴, David A. Lomas³², Stephanie J. London¹⁰, Daan W. Loth¹⁸, Sharon M. Lutz¹²⁵, David Lynch¹²⁶, William MacNee¹²⁷, Merry-Lynn McDonald¹²⁸, Deborah A. Meyers¹², John D. Newell¹¹⁷, Borge G. Nordestgaard^{129,130}, George T. O'Connor^{33,34}, Ma'en Obeidat¹³, Yeon-Mok Oh¹²³, Peter D. Paré^{13,131}, Massimo Pistolesi¹³², Dirkje S. Postma²³, Milo Puhan¹³³, Elizabeth Regan¹³⁴, Stephen S. Rich⁴⁶, Joon Beom Seo¹³⁵, Andrea Short¹³⁶, Edwin K. Silverman^{1,24}, David Sparrow⁴⁰, Berend Stoel¹³⁷, David P. Strachan⁴¹, Nicola Sverzellati¹³⁸, Ruth Tal-Singer⁴², Gerben ter Riet¹³⁹, Yohannes Tesfaigzi¹⁷, Martin D. Tobin^{5,49}, Edwin J.R. Van Beek¹⁴⁰, Bram van Ginneken¹⁴¹, Jørgen Vestbo⁴³, Claus F.

Vogelmeier¹⁴², Louise V. Wain^{5,49}, Adam Wanner¹⁴³, George Washko¹⁴⁴, Els Wauters¹⁴⁵, Emiel FM Wouters¹⁴⁶, Robert P. Young¹⁴⁷, Loems Zeigler-Heitbrock¹⁴⁸

97 Respiratory Institute, Hospital Clinic, University of Barcelona, IDIBAPS, CIBERES, Spain

98 University of North Carolina at Chapel Hill, Medicine, Chapel Hill, NC, USA

99 Salford Royal NHS Foundation Trust, Salford, UK

100 Manchester Academic Health Sciences Centre, The University of Manchester, Manchester, UK

101 Department of Internal Medicine V - Pulmonology, Allergology and Critical Care Medicine, Saarland University, Homburg, Germany

102 Department of Respiratory Medicine, Allergy and Thoracic Surgery, Glenfield Hospital, University of Leicester, Leicester, UK

103 Biomedical Imaging Group Rotterdam, Departments of Radiology and Medical Informatics, Erasmus MC, Rotterdam, the Netherlands

104 Department of Computer Science, University of Copenhagen, Copenhagen, Denmark

105 Department of Radiology, University of British Columbia, Canada

106 Department of Genetic Medicine and Division of Pulmonary and Critical Care Medicine, Department of Medicine, Weill Cornell Medical College, New York, NY, USA

107 Department of Respiratory Medicine, University Medical Center Utrecht, Utrecht, the Netherlands

108 Department of Respiratory Medicine, Herlev and Gentofte Hospital, Copenhagen, Denmark

109 Department of Electrical and Computer Engineering, Northeastern University, Boston, MA, USA

110 Morehouse School of Medicine, Atlanta, GA, USA

111 ISGlobal, Barcelona, España

112 Universitat Pompeu Fabra (UPF), Barcelona, España

113 CIBER Epidemiología y Salud Pública (CIBERESP), Barcelona, España

114 Department of Radiology, Hôpital Erasme, Université libre de Bruxelles, Belgium

115 Department of Radiology, Maastricht University Medical Center, Maastricht, the Netherlands

116 Department of Medicine, Johns Hopkins University, Baltimore, MD, USA

117 Department of Radiology, University of Iowa, Iowa City, IA, USA

118 School of Life Sciences, The University of Nottingham, Nottingham, UK

119 Department of Diagnostic and Interventional Radiology, University of Heidelberg, Translational Lung Research Center Heidelberg, Heidelberg, Germany

120 Department of Pulmonary Diseases and Clinical Allergology, Turku University Hospital, University of Turku, Turku, Finland

121 Vesalius Research Center (VRC), VIB, Leuven, Belgium

122 Laboratory for Translational Genetics, Department of Oncology, KU Leuven, Leuven, Belgium

123 Department of Pulmonary and Critical Care Medicine and Clinical Research Center for Chronic Obstructive Airway Diseases, Asan Medical Center, University of Ulsan College of Medicine, Songpa-gu, Seoul, Republic of Korea

124 Division of Pediatric Pulmonary Medicine, Department of Pediatrics, Golisano Children's Hospital at Strong, University of Rochester Medical Center, Rochester, NY, USA

- 125 Department of Population Medicine, Harvard Pilgrim Health Care Institute and Harvard Medical School, Boston, MA, USA
- 126 Department of Radiology, National Jewish Health, Denver, CO, USA
- 127 Department of Respiratory Medicine, University of Edinburgh, Edinburgh, UK
- 128 Division of Pulmonary, Allergy and Critical Care Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA
- 129 Department of Clinical Biochemistry and the Copenhagen General Population Study, Herlev and Gentofte Hospital, Copenhagen University Hospital, Herlev, Denmark
- 130 Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
- 131 University of British Columbia, Department of Medicine, Institute for Heart and Lung Health, St. Paul's Hospital, Vancouver, BC, Canada
- 132 Department of Clinical and Experimental Medicine, University Hospital Careggi, Largo Brambilla 1, 50134 Florence, Italy
- 133 Epidemiology, Biostatistics and Prevention Institute (EBPI), University of Zurich, Zurich, Switzerland
- 134 Department of Medicine, Division of Rheumatology, National Jewish Health, Denver, CO, USA
- 135 Department of Radiology and Research Institute of Radiology, Asan Medical Center, University of Ulsan College of Medicine, Songpa-gu, Seoul, Republic of Korea
- 136 School of Social Sciences, University of Manchester, Manchester, UK
- 137 Leiden University Medical Center Leiden, the Netherlands
- 138 Radiology, Department of Medicine and Surgery, University of Parma, Italy
- 139 Department of General Practice, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands
- 140 Edinburgh Imaging, University of Edinburgh, Edinburgh, UK
- 141 Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen, the Netherlands
- 142 University of Marburg, Pulmonary Diseases, Marburg, Germany
- 143 Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, Department of Medicine, University of Miami, Miller School of Medicine, Miami, Florida, USA
- 144 Department of Radiology, Brigham and Women's Hospital, Boston, MA, USA
- 145 Laboratory of Pneumology, Department of Chronic Diseases, Metabolism and Ageing, KU Leuven, Belgium
- 146 Respiratory Medicine, Maastricht University Medical Center, the Netherlands
- 147 School of Biological Sciences and Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand
- 148 EvA Study Center, Helmholtz Zentrum Muenchen, Gauting, Germany

Editorial summary:

Genome-wide analysis of chronic obstructive pulmonary disease identifies 82 loci, 35 of which are new. Integration of gene expression and genomic annotation data shows enrichment of signals in lung tissue, smooth muscle and several lung cell types.